

1 **Reciprocal Control of Motility and Biofilm Formation by the PdhS2**

2 **Two-Component Sensor Kinase of *Agrobacterium tumefaciens***

3
4 Jason E. Heindl^{1,2}, Daniel Crosby², Sukhdev Brar², Tiyan Singletary², Daniel Merenich²,
5 Justin L. Eagan¹, Aaron M. Buechlein³, Eric L. Brugler⁴,
6 Christopher M. Waters⁴ and Clay Fuqua^{1*}

7
8 ¹Department of Biology
9 Indiana University
10 Bloomington, IN 47405, USA

11
12 ²Department of Biological Sciences
13 University of the Sciences
14 Philadelphia, PA 19104, USA

15
16 ³Center for Genomics and Bioinformatics
17 Indiana University
18 Bloomington, IN 47405

19
20 ⁴Department of Microbiology and Molecular Genetics
21 Michigan State University
22 East Lansing, MI 48824, USA

23

24 Running title: *Agrobacterium* PdhS2 regulates motility and biofilms

25 Keywords: Development, sensor kinase, phosphorelay, *Agrobacterium tumefaciens*,
26 biofilm, motility

27 *Address for correspondence: Clay Fuqua, Dept. Biol., 1001 E. 3rd St., Jordan Hall 142,
28 Indiana Univ., Bloomington, IN 47405-1847. Tel: 812-856-6005, FAX: 812-855-6705, E-
29 mail: cfuqua@indiana.edu

30

31 Current addresses: J.E.H., Dept. Biol. Sci., Univ. Sci, Philadelphia, PA; E.L.B., Dept.
32 Bio. Sci., Univ. Idaho, Moscow, ID 83844

33 Word count 9275 (without abstract, importance, acknowledgements, figure legends or
34 references):

35 6 Figures, 2 Tables, 10 Supp. Figures, 3 Supp. Tables

36

37

ABSTRACT

38
39 A core regulatory pathway that directs developmental transitions and cellular
40 asymmetries in *Agrobacterium tumefaciens* involves two overlapping, integrated
41 phosphorelays. One of these phosphorelays putatively includes four histidine sensor
42 kinase homologues, DivJ, PleC, PdhS1, and PdhS2, and two response regulators, DivK
43 and PleD. In several different alphaproteobacteria, this pathway influences a conserved
44 downstream phosphorelay that ultimately controls the phosphorylation state of the CtrA
45 master response regulator. The PdhS2 sensor kinase reciprocally regulates biofilm
46 formation and swimming motility. In the current study the mechanisms by which the *A.*
47 *tumefaciens* sensor kinase PdhS2 directs this regulation are delineated. PdhS2 lacking
48 a key residue for phosphatase activity is markedly deficient in proper control of
49 attachment and motility phenotypes, whereas a kinase-deficient PdhS2 mutant is only
50 modestly affected. A genetic interaction between DivK and PdhS2 is revealed,
51 unmasking one of several connections between PdhS2-dependent phenotypes and
52 transcriptional control by CtrA. Epistasis experiments suggest that PdhS2 can function
53 independently of the CckA sensor kinase, the cognate sensor kinase for CtrA which is
54 inhibited by DivK. PdhS2 dynamically localizes to the daughter cell pole in dividing cells.
55 Global expression analysis of the *pdhS2* mutant reveals a restricted regulon, functioning
56 through CtrA to separately control motility and regulate levels of the intracellular signal
57 cyclic diguanylate monophosphate (cdGMP), thereby affecting production of adhesive
58 polysaccharides and attachment. We hypothesize that in *A. tumefaciens* the CtrA
59 regulatory circuit has expanded to include additional inputs through addition of PdhS-

60 type sensor kinases, likely fine-tuning the response of this organism to the soil

61 microenvironment.

62

63 **IMPORTANCE**

64 Bacterial developmental processes, such as morphological transformations and
65 behavioral transitions, are tightly regulated. In many alphaproteobacteria cell division
66 and development are coordinated by a specific suite of conserved histidine kinases and
67 their partnered regulatory proteins. Here we describe how the histidine kinase PdhS2 of
68 *Agrobacterium tumefaciens* regulates complex phenotypes including biofilm formation
69 and motility. PdhS2 genetically interacts with a single-domain response regulator, DivK,
70 and the intracellular signal cyclic diguanylate monophosphate. PdhS2 dynamically
71 localizes to the new pole of recently divided cells, contributing to the regulatory
72 processes that dictate whether these cells remain motile or initiate biofilm formation.
73 These findings expand our understanding of the complex network that integrates cell
74 division and developmental control in *A. tumefaciens* and related alphaproteobacteria.

75

76

77

78

79

INTRODUCTION

80 Bacteria are sometimes considered to be elementary life forms, with simple body plans,
81 streamlined reproductive cycles, and monolithic behavior when compared with higher
82 eukaryotes. To the contrary, many bacteria can exhibit a remarkable diversity of
83 developmental complexity, both temporal and morphological (1, 2). Even bacterial
84 species whose cells appear morphologically uniform, such as rod-shaped *Escherichia*
85 *coli* or coccoid *Staphylococcus aureus*, possess distinct cellular architectures as well as
86 intricately timed cell division programs, and a large number of bacteria can form
87 multicellular biofilms (3, 4). Developmental processes in bacteria, as in higher
88 eukaryotes, are driven by factors that may be considered both cell-intrinsic and cell-
89 extrinsic. Intrinsic factors include genomic and proteomic content, while extrinsic factors
90 comprise environmental conditions, such as pH and temperature, which cells sense and
91 to which they respond (5).

92 Members of the *Alphaproteobacteria* group include host-associated pathogens
93 (e.g. *Brucella* sp., *Bartonella* sp.), host-associated commensals (e.g. *Sinorhizobium* sp.,
94 *Bradyrhizobium* sp.), and free-living aquatic and marine bacteria (e.g. *Caulobacter* sp.,
95 *Rhodobacter* sp., *Ruegeria* sp.). It is now recognized that several alphaproteobacteria
96 divide asymmetrically, during which cells elongate, duplicate and segregate their
97 genomic content between two non-equivalent compartments of predivisional cells, and
98 finally generate two cells by cytokinesis (6, 7). Notably, cellular components are
99 unevenly distributed between the two daughter cells during cell division, including
100 surface structures (e.g. flagella and polar polysaccharides), cell wall components (e.g.
101 peptidoglycan), and even cytoplasmic complexes (e.g. heat shock proteins). For

102 example, there may be a clear segregation of existing organelles to one daughter cell
103 while the second cell generates these structures *de novo* (6, 8-10). Although the
104 specific details may vary among different taxa, the end result is the production of a
105 young daughter cell and a comparatively aging mother cell. Not only does this uneven
106 division partition senescence among the products of cell division, but it also allows for
107 the generation of functionally distinct cell types. For example, in *Caulobacter crescentus*
108 the non-motile stalked cell type can attach to surfaces using its polar adhesin called the
109 holdfast (11). This stalked cell then serves as the mother cell during multiple rounds of
110 cell division, generating and releasing motile swarmer cells upon each cytokinetic event
111 (12). Motile swarmer cells are prohibited from entering the cell division cycle until
112 differentiation into the non-motile stalked form (13, 14).

113 Underlying asymmetric cell division is subcellular differentiation that includes
114 localization of specific regulatory proteins to programmed locations within each cell (15).
115 Prominent among these in many alphaproteobacteria are components of two
116 overlapping phosphorelays, the first which functions through the response regulators
117 DivK and PleD (the DivK-PleD relay) and the second which functions primarily through
118 the response regulator CtrA (the CtrA relay). The pathways are connected through
119 DivK, which controls initiation of the CtrA relay by regulating its cognate sensor kinase
120 CckA (16, 17). Collectively we refer to these two relays as the DivK-CtrA pathway. In
121 the well-studied *C. crescentus* system the membrane-associated sensor histidine
122 kinases PleC and DivJ control the phosphorylation state of DivK and PleD, and localize
123 to opposing poles of the predivisional cell (18-21). Through antagonistic kinase and
124 phosphatase activities on DivK and PleD, their target response regulators, PleC and

125 DivJ inversely manifest their activity on the most downstream component of the DivK-
126 CtrA pathway, the response regulator CtrA (22-25). DivJ is retained at the stalked cell
127 pole and serves as a DivK/PleD kinase, increasing the DivK~P concentration and
128 diminishing CtrA~P levels in this region of the cell (Fig. 1A). Conversely, PleC localizes
129 to the pole distal to the stalk, where the single polar flagellum is assembled,
130 dephosphorylating DivK, leading to increased CtrA~P levels and activity. Phospho-CtrA
131 binds to the replication origin thereby preventing DNA replication, and also acts as a
132 transcriptional regulator for many genes, including activating those for assembly of the
133 flagellum and motility (26-28). The CtrA relay is also influenced by the DivK-PleD relay
134 through levels of the second messenger cyclic diguanylate monophosphate (cdGMP).
135 DivJ-dependent phosphorylation of PleD at the stalk pole of the predivisional cell
136 stimulates its diguanylate cyclase activity, resulting in higher levels of cdGMP at this
137 end of the cell. The CckA kinase that initiates the CtrA relay is also biased away from its
138 kinase and towards its phosphatase activity by direct allosteric control through high
139 levels of cdGMP, thereby reinforcing a CtrA~P gradient, relatively low at the stalk pole
140 and increasing towards the distal pole (29-34) (Fig. 1A).

141 *Agrobacterium tumefaciens* is a plant pathogen of the *Alphaproteobacteria* class
142 that is not stalked, but like *C. crescentus*, divides asymmetrically generating a motile
143 daughter cell from a mother cell (6). As a facultative pathogen, the *A. tumefaciens*
144 lifestyle substantially differs from that of the freshwater oligotroph *C. crescentus*.
145 Nonetheless core components of the DivK-CtrA pathway are well conserved in *A.*
146 *tumefaciens*, including three non-essential PleC/DivJ homologue sensor kinase (PdhS)
147 homologues PleC (Atu0982), PdhS1 (Atu0614), and PdhS2 (Atu1888). The *divJ* gene

148 (Atu0921) is essential in *A. tumefaciens* (35, 36). We have previously shown that the
149 three non-essential PdhS homologues have distinct roles in the normal cellular
150 development of *A. tumefaciens* (35). Mutants in PleC and PdhS1, as well as the *A.*
151 *tumefaciens* DivK homologue, all manifested marked effects on cell division, with
152 branched and elongated cells, as well as deficiencies in motility and biofilm formation.
153 To date the essentiality of *divJ* has precluded exhaustive phenotypic analysis of its role
154 (35). The fourth PdhS family member, PdhS2, does not appear to participate in
155 regulation of cell division as all cells are morphologically wild-type in appearance (35).
156 Loss of PdhS2, however, results in dramatically increased attachment and biofilm
157 formation, and a simultaneous dramatic reduction in motility. Reciprocal regulation of
158 these phenotypes is often a hallmark of regulation by cdGMP (37). In this work we
159 further explore the mechanism by which PdhS2 regulates attachment and motility. Our
160 results genetically connect DivK with PdhS2 and transcriptional profiling clearly
161 implicates CtrA as their downstream regulatory effector. We also show a clear
162 intersection of PdhS2 activity and the activity of several diguanylate cyclases,
163 suggesting that PdhS2 and cdGMP coordinately regulate biofilm formation and motility
164 in *A. tumefaciens*. Finally, we observe that PdhS2 dynamically localizes to the newly
165 generated poles of both the new daughter cell and the mother cell following cytokinesis.
166 Collectively, our findings suggest that PdhS2 activity is specifically required for proper
167 development of motile daughter cells.

168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190

RESULTS

Mutational analysis of PdhS2 reveals coordinate regulation through kinase and phosphatase activities. Members of the PdhS family of sensor histidine kinases contain a conserved HATPase_c catalytic domain at their carboxyl termini and an upstream conserved HisKA dimerization/phosphoacceptor domain. Many sensor kinases exhibit bifunctional catalytic activity, alternately acting as kinase or phosphatase, and *C. crescentus* PleC is one such example (18, 22, 38). Multiple sequence alignment of the HisKA domain from the *A. tumefaciens* and *C. crescentus* PdhS family kinase homologues reveals a high level of conservation of this domain including the phospho-accepting histidine residue (H271 of PdhS2) and a threonine residue predicted to be important for phosphatase activity (T275 of PdhS2) (Fig. 1B).

To test the requirement of the conserved phospho-accepting histidine for PdhS2 activity we mutated this residue to alanine (H271A). Ectopic expression of PdhS2^{H271A} (plasmid-borne *P*_{lac}-*pdhS2*, kinase-negative, K; phosphatase-positive, P⁺) effectively complemented the attachment and motility phenotypes of the Δ *pdhS2* mutant similar to wild type *pdhS2* (Fig. 2A). These data indicate that this histidine residue is not crucial for PdhS2 regulation of swimming motility and biofilm formation. When *pdhS2* is ectopically expressed in the wild type, it causes a slight but significant stimulation of biofilm formation, and the *pdhS2*^{H271A} (K-P⁺) mutation reverses this effect.

Efficient phosphatase activity of many sensor kinases requires a conserved threonine residue roughly one α -helical turn (4 residues) downstream of the phospho-accepting histidine residue (39, 40). We therefore mutated this conserved threonine

191 residue to alanine (Thr275A). In contrast to the PdhS2^{H271A} mutant protein (K⁺P⁺),
192 equivalent ectopic expression of the PdhS2^{T275A} allele (K⁺P⁻) failed to complement the
193 $\Delta pdhS2$ motility and attachment phenotypes, and in fact exacerbated them (Fig. 2A).
194 When expressed in wild type, the PdhS2^{T275A} allele (K⁺P⁻) caused modest stimulation of
195 biofilm formation and slightly decreased motility. A double mutant allele of PdhS2 with
196 both the histidine and threonine residues mutated (K⁻P⁻) had no effect on these
197 phenotypes (Fig. S1). Together these results suggest that it is the balance of kinase and
198 phosphatase activity that dictates PdhS2 control over its targets, with the kinase
199 stimulating biofilm formation and decreasing motility, and the phosphatase activity
200 diminishing biofilm formation and promoting motility. The phosphatase activity however,
201 appears to play the dominant role under laboratory culture conditions.

202

203 **Mutations in *divK* are epistatic to *pdhS2* mutations.** Members of the PdhS family of
204 sensor kinases were originally identified based on homology with their namesakes DivJ
205 and PleC of *C. crescentus* (41, 42) (Fig. 1B). Based on this homology all PdhS family
206 members are predicted to interact with the single domain response regulator DivK (42)
207 and also interact with the diguanylate cyclase response regulator PleD. Prior work from
208 our laboratory has shown that both swimming motility and adherent biomass are
209 diminished in the $\Delta divK$ mutant, implying that DivK activity is required for proper
210 regulation of these phenotypes in *A. tumefaciens* (35). In contrast, PdhS2 inversely
211 regulates these phenotypes; a $\Delta pdhS2$ mutant is non-motile but hyperadherent. To
212 determine whether PdhS2 genetically interacts with DivK we constructed a
213 $\Delta divK \Delta pdhS2$ mutant and compared swimming motility and biofilm formation in this

214 strain to wild-type and parental single deletion strains (Fig. 2B). As reported, loss of
215 either *divK* or *pdhS2* reduced swimming motility as measured by swim ring diameter on
216 motility agar. Biofilm formation on PVC coverslips in the $\Delta divK$ mutant was diminished
217 relative to the wild-type C58 strain while for the $\Delta pdhS2$ mutant it was dramatically
218 increased. The $\Delta divK\Delta pdhS2$ mutant was similar to the $\Delta divK$ mutant in both assays,
219 with no significant difference in the efficiency of either swimming motility or biofilm
220 formation between the two strains. These data support the proposed genetic interaction
221 between *divK* and *pdhS2*, with the *divK* mutation epistatic to *pdhS2* for biofilm formation
222 and swimming motility.

223 Swim ring diameters of the $\Delta divK$ and $\Delta divK\Delta pdhS2$ mutants were decreased by
224 ~20% compared to wildtype whereas the decrease in $\Delta pdhS2$ swim ring diameters was
225 ~40% compared to wildtype, suggesting that the nature of the defect in swimming
226 motility differs between these two classes of mutants and that loss of *divK* partially
227 restores motility in the absence of *pdhS2*. Indeed, it was earlier noted that although both
228 the $\Delta divK$ and the $\Delta pdhS2$ single deletion mutants produce polar flagella, very few
229 $\Delta pdhS2$ mutant bacteria were observed to be motile under wet-mount microscopy
230 implying that the swimming defect is due to diminished flagellar activity rather than
231 flagellar assembly (35). The $\Delta divK$ mutant, however, was readily observed to be motile
232 under wet-mount microscopy. Similarly, the $\Delta divK\Delta pdhS2$ mutant generates polar
233 flagella and its motility is readily observed under wet-mount microscopy. Both the $\Delta divK$
234 and $\Delta divK\Delta pdhS2$ mutants, and not the $\Delta pdhS2$ mutant, generate aberrant cell
235 morphologies including elongated and branched cells (35) (Fig. S2).

236 Further support for a genetic interaction between PdhS2 and DivK was provided
237 by plasmid-borne, wild-type PdhS2 expressed ectopically from a P_{lac} promoter. Induced
238 expression of *pdhS2* rescues swimming motility and returns biofilm formation closer to
239 wild type levels in the $\Delta pdhS2$ mutant, albeit incompletely (Fig. 2A). However, as
240 predicted from the $\Delta divK \Delta pdhS2$ phenotypes, plasmid-borne provision of PdhS2 in the
241 $\Delta divK$ mutant had no significant effect on either biofilm formation or swimming motility
242 (Fig. 2C). Expression of either the kinase-null or the phosphatase-null allele of PdhS2 in
243 the $\Delta divK$ background similarly had no effect on biofilm formation or swimming motility
244 (Fig. 2C).

245

246 **Kinase-locked allele of CckA does not suppress *pdhS2* phenotypes.** One key
247 PdhS target among multiple bacterial taxa is the hybrid histidine kinase CckA. CckA
248 exhibits dynamic regulation dependent upon both phosphorylation status of DivK and
249 local levels of cdGMP (31). CckA ultimately serves as either a source or a sink for CtrA
250 phosphorylation through a phosphorelay that includes the histidine phosphotransferase
251 ChpT (29). Previously we identified a mutation in CckA that results in a kinase-locked
252 allele which is insensitive to regulation by DivK and cdGMP, CckA^{Y674D} (31, 35).
253 Expression of this allele in the $\Delta pleC$ background suppressed the swimming motility
254 defect of the $\Delta pleC$ strain but had no effect on swimming motility in the $\Delta divK$
255 background (35). These results were consistent with PleC activity proceeding through
256 DivK and with DivK negatively regulating CckA kinase activity. We reasoned that if
257 PdhS2 similarly functioned through DivK and CckA, expression of CckA^{Y674D} in the
258 $\Delta pdhS2$ background would suppress the motility and biofilm phenotypes of this strain.

259 However, induced expression of wild-type CckA or the CckA^{Y674D} allele only marginally
260 impacted these phenotypes (Fig. S3 and S4). These observations suggest that PdhS2
261 functions differently than PleC.

262

263 **PdhS2 and DivJ localize to the pole of *A. tumefaciens*.** A mechanism for
264 establishing and maintaining developmental asymmetries in bacteria is the differential
265 polar localization of proteins with opposing functionalities (43, 44). Several members of
266 the PdhS family of sensor kinases localize to one or both bacterial poles (18, 22, 45).
267 Using a full-length PdhS2-GFP fusion that retains wild type functionality, expressed
268 from *P_{lac}* on a low copy number plasmid, we tracked localization of PdhS2 in *A.*
269 *tumefaciens* following IPTG induction (Fig. 3A). In both wild-type (data not shown) and
270 $\Delta pdhS2$ backgrounds PdhS2-GFP localized primarily to the new pole of predivisional
271 cells. Time-lapse microscopy of the $\Delta pdhS2$ mutant expressing PdhS2-GFP revealed
272 apparent dynamic relocation of PdhS2-GFP to the newly generated pole of the
273 daughter cell coincident with cytokinesis. In the mother cell a new focus of PdhS2-GFP
274 subsequently accumulates at the new pole generated following septation and daughter
275 cell release. These time-lapse experiments clearly indicate that PdhS2-GFP localizes to
276 the actively growing pole of the cell, and is lost at that pole as it developmentally
277 matures and the cell proceeds to the predivisional state. Following cytokinesis PdhS2-
278 GFP localizes to the newly generated, younger poles of both the daughter cell and the
279 mother cell. This dynamic localization is consistent with PdhS2 activity being restricted
280 to the motile-cell compartment of predivisional cells and to newly generated motile cells.

281 Since PdhS2 localizes to the new pole of dividing cells and primarily requires its
282 phosphatase activity there likely exist one or more old pole-localized kinases opposing
283 PdhS2 activity. The most obvious candidate for this is DivJ, which localizes to the old
284 pole in *C. crescentus* and acts as a DivK kinase in both *C. crescentus* and *S. meliloti*
285 (42, 46). Time-lapse microscopy of a full length DivJ-GFP fusion in wild-type *A.*
286 *tumefaciens* reveals localization to the old pole in mother cells that is not redistributed
287 over the course of multiple cell division cycles (Fig. 3B). Our findings are confirmed by a
288 recent report of similar localization patterns for PdhS2 and DivJ, which also
289 demonstrates PdhS1 localization to the old pole of the bacterium, similar to DivJ (47).

290

291 **Expression of predicted CtrA-dependent promoters.** The known architecture of the
292 DivK-CtrA pathway predicts that PdhS2 impacts developmental phenotypes through the
293 transcriptional regulator CtrA. In *C. crescentus*, CtrA is known to directly regulate at
294 least 55 operons, acting as either an activator or repressor of transcription, and to
295 control DNA replication (22, 28). *A. tumefaciens* CtrA is predicted to act similarly,
296 binding to DNA in a phosphorylation-dependent manner and regulating DNA replication
297 and transcription. *A. tumefaciens* CtrA is 84% identical to *C. crescentus* CtrA at the
298 amino acid level and purified *C. crescentus* CtrA binds to a site upstream of the *A.*
299 *tumefaciens ccrM* gene (48). Furthermore, computational analysis of multiple
300 alphaproteobacterial genomes uncovered numerous cell cycle regulated genes
301 preceded by a consensus CtrA binding site (49). We therefore evaluated CtrA activity by
302 examining the transcription of several known and predicted CtrA-dependent promoters
303 from both *C. crescentus* and *A. tumefaciens* in wild-type, $\Delta pdhS2$, and $\Delta divK$ *A.*

304 *tumefaciens* strain backgrounds. The *ccrM*, *ctrA*, and *pilA* promoters from *C. crescentus*
305 were chosen to represent CtrA-activated promoters likely to be similarly regulated in *A.*
306 *tumefaciens* (13, 14, 50, 51). In the $\Delta pdhS2$ background, expression levels from both
307 the *ctrA* and *pilA* promoters from *C. crescentus* were significantly reduced while
308 transcription from the *C. crescentus ccrM* promoter was unchanged (Table 1). In the *A.*
309 *tumefaciens* $\Delta divK$ background the *C. crescentus ccrM* and *ctrA* promoters exhibited
310 increased activity while the *pilA* promoter was unchanged (Table 1). These data are
311 consistent with *A. tumefaciens* CtrA regulating transcription of known CtrA-dependent
312 promoters, and with PdhS2 and DivK inversely regulating CtrA activity in *A.*
313 *tumefaciens*.

314 From *A. tumefaciens* the *ccrM* promoter is the only promoter for which prior
315 experimental data suggest CtrA-dependent regulation, thus this promoter was selected
316 for analysis (48). In addition to *ccrM*, putative *A. tumefaciens* promoters for *ctrA* and
317 *pdhS1* were selected for analysis based on the presence of at least one predicted CtrA
318 binding site as well as hypothesized cell cycle regulation of these loci. Transcriptional
319 activity from the *A. tumefaciens ctrA* and *pdhS1* promoter constructs showed inverse
320 regulation in the $\Delta pdhS2$ and $\Delta divK$ backgrounds, with expression decreased from the
321 *ctrA* promoter and increased for the *pdhS1* promoter in the $\Delta pdhS2$ mutant, and exactly
322 reversed in the $\Delta divK$ mutant. Although absence of *pdhS2* had little effect on the *A.*
323 *tumefaciens ccrM* promoter, transcription from this promoter was significantly increased
324 in the $\Delta divK$ background (Table 1). These data are congruent with the above data for *C.*
325 *crescentus* CtrA-dependent promoters and further support CtrA regulation of cell cycle-
326 responsive genes in *A. tumefaciens*.

327
328 **Global transcriptional analysis of PdhS2 activity.** To determine the effect of PdhS2
329 activity on the *A. tumefaciens* transcriptome we used whole genome microarrays. Gene
330 expression was compared between WT and $\Delta pdhS2$ strains grown to exponential phase
331 in minimal media. Of 5338 unique loci represented on the arrays 39 genes were
332 differentially regulated above our statistical cut-offs (P values, ≤ 0.05 ; \log_2 ratios of $\geq \pm$
333 0.50; Table 2). Of these, 24 genes were significantly upregulated, indicating negative
334 regulation by PdhS2. Upregulated genes included *dgcB*, previously shown to contribute
335 to elevated biofilm formation in hyperadherent *A. tumefaciens* mutants disrupted in the
336 motility regulators VisN and VisR (52). Also upregulated was Atu3318, encoding a
337 LuxR-type transcription factor, that similar to *dgcB* was previously identified by its
338 elevated levels in *visNR* null mutants. Downregulated genes in the *pdhS2* mutant
339 included six succinoglycan biosynthetic genes, consistent with our previous results
340 showing positive regulation of succinoglycan production by PdhS2 (35).

341 To determine whether any of these 39 genes were putatively regulated by CtrA
342 we scanned a sequence window from 500 bp upstream of the start codon to 100 bp into
343 the coding sequence for plausible CtrA binding sites. CtrA binding sites were defined
344 using the conserved alphaproteobacterial CtrA recognition sequence 5'-
345 TTAANNNNNGTTAAC-3' (48, 49). Sequences containing seven or more of the
346 conserved nucleotides in this motif were deemed plausible candidates. Using these
347 parameters 15 differentially transcribed loci are expressed from promoters (some from
348 upstream genes in the operon) with putative CtrA binding sites and are thus putatively
349 directly regulated by CtrA, including *dgcB* and Atu3318, as well as all five of the

350 downregulated succinoglycan biosynthetic genes (Fig. S5; Table 2). We also identified
351 numerous CtrA half-sites containing the sequence 5'-TTAA-3'. In *C. crescentus* CtrA
352 has been shown to bind to such half motifs resulting in transcriptional effects (53).
353 Twenty-eight promoters contained at least one CtrA half-site (Table 2).

354 To extend our microarray results we measured transcription of translational
355 fusions to β -galactosidase for *dgcB* and *Atu3318*, in wild-type, $\Delta pdhS2$, and $\Delta divK$ strain
356 backgrounds (Table 1). In both cases β -galactosidase activity increased in the $\Delta pdhS2$
357 mutant, corroborating the microarray results. Furthermore, activity decreased from each
358 promoter fusion in the $\Delta divK$ background supporting inverse regulation by PdhS2 and
359 DivK at these promoters. Finally, to confirm a role for CtrA in transcriptional regulation
360 by PdhS2 and DivK we mutated one CtrA half-site (-126 from start codon, TTAA to
361 AATT) in the *dgcB* promoter region and evaluated transcription from this promoter fused
362 to β -galactosidase as above. Surprisingly, activity from this mutated promoter was
363 diminished in all backgrounds tested (wild-type, $\Delta pdhS2$, and $\Delta divK$) suggesting that
364 CtrA does interact with this site to influence transcription of *dgcB*, but that this regulation
365 is complex (Table 1). Overall these results are consistent with PdhS2 impacting the
366 motile cell developmental program through CtrA-dependent transcriptional control.

367

368 **Evaluation of CtrA protein levels.** Turnover of CtrA is known to play a role in its
369 regulatory activity in several related systems. To determine the effect of PdhS2 and
370 DivK on CtrA activity and stability in *A. tumefaciens* we evaluated its steady-state levels
371 and turnover in unsynchronized, stationary phase cultures using western blotting with
372 antibodies raised against *C. crescentus* CtrA. In stationary phase cultures CtrA levels

373 were increased in the $\Delta pdhS2$ background and decreased in the $\Delta divK$ background, but
374 these effects were quite modest. This observation is however consistent with PdhS2
375 and DivK inversely impacting CtrA accumulation or stability (Fig. 4A).

376 CtrA protein stability was evaluated following treatment of wild-type and $\Delta pdhS2$
377 cultures with chloramphenicol to inhibit translation during exponential growth. In wild-
378 type cultures, translation inhibition leads to a decline in CtrA abundance over the course
379 of 2-3 hours, diminishing to roughly 30% of the steady-state levels. Loss of *pdhS2* had
380 no effect on either final steady-state levels of CtrA following inhibition of translation or
381 the observed rate of turnover when compared with wild-type cultures under these
382 conditions (Fig. 4B).

383

384 **PdhS2 activity intersects with cyclic-di-GMP pools.** In *C. crescentus* DivJ and PleC
385 positively regulate, via phosphorylation, a second response regulator, PleD, as well as
386 DivK (22). In *C. crescentus* and *A. tumefaciens* the *divK* and *pleD* coding sequences
387 form one operon and transcriptional regulation of both genes is linked. Since several
388 PdhS kinases in these systems are predicted to interact with both DivK and PleD we
389 analyzed the effect of loss of PleD activity in the $\Delta pdhS2$ background. As reported
390 previously, deletion of *A. tumefaciens pleD* alone has only modest effects on swimming
391 motility and adherent biomass (35). Loss of *pleD* in the $\Delta pdhS2$ background had a
392 minimal effect on swimming motility (Fig. S6). Biofilm formation, however, was reduced
393 by approximately 30%, indicating that PleD contributes to the increased attachment
394 phenotype of the $\Delta pdhS2$ mutant (Fig. 5A).

395 PleD is a GGDEF motif-containing diguanylate cyclase (DGC), and thus it is
396 likely that the attachment phenotype of the $\Delta pdhS2$ mutant requires increased levels of
397 cdGMP. Earlier work from our lab identified three additional DGCs that are relevant to
398 attachment and biofilm formation: DgcA, DgcB, and DgcC (52). As seen in wild-type
399 C58, deletion of *dgcA* or *dgcB* in the $\Delta pdhS2$ background significantly decreased
400 attachment and biofilm formation, whereas loss of *dgcC* did not (Fig. 5A). These data
401 suggest that increased biofilm formation by the $\Delta pdhS2$ mutant is dependent on cdGMP
402 pools, generated through PleD, DgcA, or DgcB. Loss of *dgcB* largely abolishes the
403 increased biofilm formation of the $\Delta pdhS2$ mutant. We also compared biofilm formation
404 in $\Delta dgcB\Delta pleD$ and $\Delta pdhS2\Delta dgcB\Delta pleD$ mutant backgrounds. In the absence of both
405 DgcB and PleD biofilm formation was enhanced by loss of PdhS2 (Fig. S7). These data
406 suggest that the increased biofilm formation of a *pdhS2* mutant is dependent on a
407 cdGMP pool that is predominantly due to DgcB, but that is also under the cumulative
408 influence of multiple DGC enzymes. Swimming motility was equivalent in either wild-
409 type C58 or $\Delta pdhS2$ backgrounds in combination with mutations in *pleD*, *dgcA*, *dgcB*, or
410 *dgcC* (Fig. S6 and S7).

411 Previously we found that mutants lacking either *dgcA*, *dgcB*, or *dgcC* show
412 insignificant differences in total cytoplasmic levels of cdGMP (52). Nonetheless, loss of
413 either *dgcA* or *dgcB*, or mutation of the GGDEF catalytic site of either enzyme,
414 significantly reduced biofilm formation (52), implicating these enzymes in controlling the
415 pool of cdGMP and thereby affecting attachment. We compared cytoplasmic cdGMP
416 levels for wild-type C58, the $\Delta pdhS2$ mutant, and the $\Delta pdhS2\Delta dgcB$ mutant strain and
417 found these levels to be low, with no significant change between mutants (Fig. S8). To

418 verify that the DGC activity is responsible for the increased biofilm formation in the
419 $\Delta pdhS2$ background we expressed an allele of *dgcB* with a mutation in its GGDEF
420 catalytic motif (GGAAF; *dgcB*^{*}) that abrogates cdGMP formation and that fails to
421 complement a $\Delta dgcB$ mutant for either cdGMP formation or attachment phenotypes
422 (52). Plasmid-borne expression of wild-type *dgcB* (*P*_{lac}-*dgcB*) results in a massive
423 increase in attachment and biofilm formation in either the wild-type C58 or $\Delta pdhS2$
424 background (Fig. 5B). Expression of *dgcB*^{*} from a *P*_{lac} promoter, however, did not
425 increase biofilm formation in either background. In the $\Delta pdhS2\Delta dgcB$ mutant
426 background expression of wild-type *dgcB* increased biofilm formation to the same
427 degree seen in the wild-type and $\Delta pdhS2$ mutant. Expression of the mutant *dgcB*^{*} allele
428 in the $\Delta pdhS2\Delta dgcB$ mutant did appear to modestly affect biofilm formation, although
429 far less than with the wild-type *dgcB* allele. Swimming motility was modestly but
430 significantly reduced when the wild-type *dgcB* allele was provided *in trans* and this was
431 abolished by the *dgcB*^{*} mutation (Fig. S9). Together our data are consistent with
432 PdhS2-dependent biofilm formation and, to a lesser extent, swimming motility, being
433 mediated at least in part by cdGMP levels.

434

435 **Increased attachment in a *pdhS2* mutant requires the UPP polysaccharide.** We
436 have previously reported that PleD-stimulated attachment was due to increased levels
437 of the unipolar polysaccharide (UPP) and cellulose (52). In addition to UPP and
438 cellulose, *A. tumefaciens* produces at least three other exopolysaccharides:
439 succinoglycan, cyclic β -1, 2 glucans, β -1, 3 glucan (curdlan), as well as outer membrane
440 associated lipopolysaccharide (LPS) (54). Of these only LPS is essential for *A.*

441 *tumefaciens* growth (36). The $\Delta pdhS2$ strain was tested for the impact of each of the
442 non-essential exopolysaccharides for biofilm formation and swimming motility. The *upp*
443 mutation completely abolished attachment in both the wild type and the *pdhS2* mutant
444 (Fig. S10A). The *chvAB* mutant, known to have pleiotropic effects (55), was diminished
445 in adherence overall, but was still elevated by the *pdhS2* mutation. None of the other
446 exopolysaccharide pathways impacted adherence in either background. The decreased
447 swimming phenotype of the *pdhS2* mutant was not significantly altered for any of the
448 exopolysaccharide mutants (Fig. S10B). These results indicate that biofilm formation in
449 the $\Delta pdhS2$ strain is dependent primarily on UPP production and that the motility
450 phenotype of the $\Delta pdhS2$ mutant is not dependent on any of the known
451 exopolysaccharides.

452

453

454 **DISCUSSION**

455 **PdhS2 regulates attachment and motility predominantly by its phosphatase**

456 **activity and through CtrA.** Regulation of the developmental program of many
457 alphaproteobacteria centers on the global transcriptional regulator CtrA (43, 49, 56, 57).
458 CtrA activity is controlled, indirectly, through a series of phosphotransfer reactions
459 dependent on one or more PdhS-type histidine kinases. Here we show that PdhS2, one
460 of at least four PdhS family kinases from *A. tumefaciens*, regulates motility and
461 attachment at least in part through fine-tuning of CtrA activity, thereby impacting the
462 CtrA regulon. We demonstrate that null mutations of the single domain response
463 regulator *divK* are epistatic to *pdhS2* mutations in *A. tumefaciens*. Mutation of specific
464 DGCs also reverse the phenotypes of *pdhS2* mutants, suggesting that elevated
465 attachment and decreased motility are mediated through cdGMP pools. The
466 phosphatase activity of PdhS2 is predominantly responsible for its function during
467 laboratory culture growth. It is worth noting however, that strains bearing the
468 phosphatase-null and kinase-null alleles of PdhS2 do not phenocopy one another nor
469 the $\Delta pdhS2$ mutant strains, supporting distinct roles for both enzymatic activities. This is
470 in contrast to mutant alleles of *pleC* in *C. crescentus* (46, 58, 59). Fine-scale
471 determination of the timing, specificity, and regulation of both phosphatase and kinase
472 activities await further experimentation.

473

474 **Indirect regulation of CtrA by PdhS2.** Our data support altered CtrA activity as
475 responsible for many of the *pdhS2*-dependent transcriptional responses, and through
476 these motility and attachment. A significant fraction of the differentially expressed genes
477 had presumptive CtrA binding sites in their upstream regions. Several of the genes

478 examined directly were dysregulated in both *pdhS2* and *divK* mutants, but usually in the
479 opposite directions. We predict that both DivK and PdhS2 function through affecting the
480 phosphorylation state of CtrA. In *A. tumefaciens* CtrA activates certain promoters (e.g.
481 succinoglycan synthetic genes and *ctrA*) while repressing others (e.g. *dgcB*, Atu3318,
482 and *pdhS1*). Although the *pdhS2* and *divK* mutations do slightly change steady state
483 levels of CtrA, our findings suggest that changes in CtrA stability do not explain the
484 resulting phenotypes. We posit that the phosphorylation state of CtrA is the dominant
485 mechanism by which its activity is affected in these mutants. There are several
486 examples in *C. crescentus* where altered CtrA activity is observed without significant
487 changes in CtrA abundance (36, 60, 61). There are also several examples in both *C.*
488 *crescentus* and *S. meliloti* where altered PdhS kinase activity results in both perturbed
489 activity and altered abundance of CtrA (42, 62). The subtle effects on CtrA abundance
490 coupled with the modest, but significant, effects we observed for several CtrA-
491 dependent promoters, suggest that PdhS2 regulation of CtrA activity may be restricted
492 to a very tight window during the cell cycle. Alternatively, the complement of remaining
493 PdhS kinases may buffer CtrA activity in the absence of *pdhS2*.

494

495 **PdhS2 influences cdGMP-dependent phenotypes.** The increased biofilm formation
496 and diminished motility in a *pdhS2* mutant is most similar to the inverse regulation
497 frequently observed for increasing internal pools of cdGMP (63). Indeed, our data
498 demonstrate a strong dependence on specific diguanylate cyclases for mediating the
499 Δ *pdhS2* hyperadherent phenotype, and transcription analysis demonstrates that *dgcB*
500 expression is elevated in this mutant. Although measurements of the cytoplasmic

501 cdGMP levels suggest that they remain low overall in the *pdhS2* mutant, it is clear that
502 mutations in *dgcB* strongly reverse the effects of the *pdhS2* mutation on attachment and
503 that, to a lesser extent, mutations in *dgcA* and *pleD* can diminish them. This suggests
504 that increased cdGMP synthesis via these enzymes may impart the effect on UPP-
505 dependent attachment. Although DgcB seems to have the dominant effect, it is
506 plausible that PdhS2 may affect PleD DGC activity through the phosphorylation state of
507 its receiver domain, similar to other PleD homologues (22, 64, 65). In *A. tumefaciens*
508 PleD has only modest effects on motility and attachment, and does not significantly
509 contribute to cell cycle control (35). Neither DgcB nor DgcA is a response regulator, and
510 it is more likely that at least for *dgcB*, its elevated expression is the mechanism through
511 which CtrA functions. Recent studies have revealed that the *C. crescentus* orthologue of
512 *A. tumefaciens* DgcB regulates holdfast synthesis in response to changes in flagellar
513 rotation (66). Thus, changes in *dgcB* levels due to mutation of *pdhS2* may be also be
514 impacting the motile to sessile transition in *A. tumefaciens*.

515 The phenotypes regulated by PdhS2 mirror those regulated by the master
516 motility regulators VisR and VisN (52). Loss of either *visN* or *visR* results in abolishment
517 of motility and a dramatic increase in attachment that is dependent on cdGMP
518 production and the UPP adhesin. However, the motility defect in *visNR* mutants is
519 predominantly transcriptional, as expression of all of the flagellar genes is dramatically
520 decreased. In contrast, none of the flagellar genes are differentially regulated in the
521 *pdhS2* mutant as measured in our microarray data, and flagella are assembled but
522 decreased in activity. The increased attachment in *visNR* mutants is however due to
523 elevated *dgcB* expression and also requires *dgcA*, through increased cdGMP and

524 elevation of UPP and cellulose biosynthesis (52). Interestingly, other target genes that
525 are derepressed in *pdhS2* mutants are also among the small fraction of the genes that
526 are increased in a *visR* mutant, such as *Atu3188*. Given the presence of CtrA boxes in
527 their upstream sequences this may suggest a common underlying mechanism.
528 Interestingly, mutation of *dgcB* or the other DGCs does not enhance the dramatically
529 impeded motility of the *pdhS2* mutant. This suggests that the loss of motility in the
530 *pdhS2* mutant is not primarily due to elevated cdGMP levels. In many systems, CtrA
531 directly regulates motility, often through flagellar gene expression (67, 68). In fact,
532 plasmid-borne expression of the *A. tumefaciens* CtrA in a *ctrA* null mutant of the marine
533 alphaproteobacterium *Ruegeria* sp. KLH11 (*ctrA* is not essential in this taxon),
534 effectively reverses its non-motile phenotype (69), indicative of its positive impact on
535 motility on this bacterium. It seems likely that the non-motile phenotype of the *A.*
536 *tumefaciens pdhS2* mutant likewise reflects a decrease in active CtrA.

537 Interestingly, as shown for *C. crescentus* and *A. tumefaciens*, elevated cdGMP
538 allosterically switches the bifunctional hybrid histidine kinase CckA from kinase to
539 phosphatase mode, thereby downregulating CtrA phosphorylation and DNA-binding
540 activity (30, 31). Thus effects on local cdGMP levels can feed back on the CtrA
541 pathway, reinforcing decreases in CtrA~P that would be coincident with increased
542 cdGMP.

543

544 **Segregation of antagonistic signaling activity promotes asymmetric development.**

545 The asymmetric division of *A. tumefaciens* and other alphaproteobacteria, producing
546 two genetically identical but phenotypically distinct daughter cells, requires well-

547 coordinated regulation of two developmental programs. The mother cell remains in a
548 terminally differentiated state, proceeding through distinct synthesis (S) and growth
549 (G1/G2) phases of the cell cycle (54, 56). During G1/G2 phase the cell elongates into a
550 predivisional cell and establishes a functional asymmetry between its two cellular poles
551 by differential localization of antagonistic homologues of the PdhS kinases. At least one
552 PdhS kinase localizes to the old pole; DivJ in *C. crescentus*, DivJ and PdhS1 in *A.*
553 *tumefaciens* (Fig. 1A and 3B), PdhS in *B. abortus*, and CbrA in *S. meliloti*, (18, 41, 47).
554 From this position these kinases can act to phosphorylate targets such as DivK and
555 PleD, indirectly inactivating CtrA (as reported for *C. crescentus*). At the opposite pole at
556 least one PdhS kinase, PleC in *C. crescentus* and PdhS2 in *A. tumefaciens* (Fig. 1A
557 and 3A), localizes and acts primarily through its phosphatase activity to
558 dephosphorylate targets, ultimately promoting CtrA stability and activity. Upon
559 cytokinesis, then, the motile daughter cell is released in a G1/G2 growth phase with
560 high levels of CtrA activity establishing a distinct transcriptional program and limiting
561 DNA replication.

562 Our data are consistent with PdhS2 acting in the motile daughter cell to prevent
563 premature activation of cell attachment processes, as well as to promote motility. PdhS2
564 dynamically localizes to the new pole of *A. tumefaciens* cells following cytokinesis while
565 DivJ, another PdhS-type kinase, localizes to the old pole of each cell. We propose that
566 together the antagonistic activities of DivJ and PdhS2 (and perhaps additional PdhS
567 homologues), coupled with their distinct localization patterns, generate a spatiotemporal
568 gradient of phospho-CtrA, thus differentially regulating the developmental program of *A.*
569 *tumefaciens* (Fig. 1A). Localized synthesis and degradation of cdGMP contributes to

570 this regulatory gradient. Prior to and after cytokinesis daughter cells would have PdhS2
571 at their flagellar pole, reinforcing the CtrA pathway, increasing CtrA~P, promoting
572 motility and preventing adhesive processes. In contrast, at the mother cell old pole after
573 PdhS2 delocalization, DivJ kinase activity would dominate, the CtrA pathway would be
574 inhibited, and lower CtrA~P levels would promote DNA replication, maintaining a
575 sessile, non-motile state. Computational models of asymmetric cell development in *C.*
576 *crescentus* support this notion, with the important *caveat* that phospho-DivK may not be
577 distributed in a gradient but rather locally restricted (23, 25, 70).

578

579 **PdhS2 may regulate CtrA activity via an alternate route.** The recognized
580 architecture of the DivK-CtrA regulatory pathway in several alphaproteobacteria,
581 coupled with our data demonstrating a genetic interaction between *divK* and *pdhS2* in
582 *A. tumefaciens*, are consistent with PdhS2, primarily through its phosphatase activity,
583 decreasing DivK phosphorylation, similar to what is predicted for the other PdhS-type
584 kinase PleC (Fig. 6, Model A). The *pdhS2* mutant phenotype is however in stark
585 contrast to the other non-essential *A. tumefaciens* PdhS-type mutants and the *divK*
586 mutant, which all cause cell branching (35). How does PdhS2 regulate the same
587 pathway so differently from the PdhS-type proteins? Possibly, spatial restriction of
588 PdhS2 activity to the new poles of mother cells, that rapidly transition to become the old
589 pole of newly formed daughter cells, imparts PdhS2 control of motility and attachment
590 processes, without strongly influencing the budding process *per se*. Alternatively,
591 PdhS2 may act via a different mechanism to influence CtrA activity.

592 An interesting possibility is that PdhS2 and DivK may work in parallel rather than
593 in series to impact CtrA activity and its target genes (Fig. 6, Model B). The apparent
594 epistasis of the *divK* mutation over the *pdhS2* mutation could result from the unfettered
595 activity of CckA in the *divK* mutant, which titrates the impact of the *pdhS2* mutation. Our
596 results in which expression of wild-type and kinase-locked CckA (CckA^{Y67D}) alleles in
597 the Δ *pdhS2* mutant only modestly impact its mutant phenotypes, support this proposal
598 (Fig. S3 and S4). The CckA^{Y67D} mutant was isolated as a spontaneous suppressor of
599 the swimming deficiency of a *pleC* mutant (35). Plasmid-borne ectopic expression of the
600 CckA^{Y67D} effectively reversed *pleC* phenotypes, in contrast to the observation that it
601 does not suppress *pdhS2* mutant phenotypes (Fig. S3 and S4). This suggests that
602 PdhS2 does not act similarly to PleC to inhibit DivK phosphorylation. A plausible
603 explanation is that PdhS2 control of CtrA activity is independent of DivK and CckA (Fig.
604 6, Model B). Although uninhibited CckA kinase activity in a *divK* mutant can overcome
605 the effect of the *pdhS2* mutation, perhaps the kinase-locked CckA^{Y67D} allele is
606 insufficiently active to do so.

607 In this model, PdhS2 intercepts the DivK-CtrA signaling axis at a node
608 downstream or independent of CckA (Fig. 6). Our findings reveal that the phosphatase
609 activity of PdhS2 is dominant in its impact on CtrA-dependent targets, suggesting that it
610 dephosphorylates a response regulator that itself is inhibitory to CtrA activity. A
611 response regulator that inhibits CtrA directly is CpdR (Fig. 6), which in *C. crescentus*
612 stimulates proteolytic turnover of CtrA (71). *A. tumefaciens* has two CpdR homologues,
613 CpdR1 and CpdR2 (Atu3883 and Atu3603, respectively). *S. meliloti* likewise maintains
614 two CpdR homologues one of which, CpdR1, impacts developmental phenotypes and

615 CtrA activity (62, 72). However, current models suggest that for CpdR in *C. crescentus*
616 and CpdR1 in *S. meliloti*, phosphorylation through ChpT decreases its ability to drive
617 CtrA degradation. Therefore, in *A. tumefaciens*, if PdhS2 acts on the pathway through
618 its phosphatase activity, dephosphorylation of CpdR1 would increase its inhibitory
619 capacity for CtrA. Mutation of *pdhS2* would then be predicted to lead to more CtrA~P
620 available to inhibit *dgcB* expression and stimulate motility, generating the opposite of
621 the non-motile, hyperadherent phenotypes we observe. It is formally possible that in *A.*
622 *tumefaciens* CpdR functions differently than its orthologues in *C. crescentus* or *S.*
623 *meliloti*, or that the PdhS2 target is a different response regulator.

624 A plausible alternative target for PdhS2 is CpdR2 (Atu3603). The CpdR2
625 response regulator of *S. meliloti* does not impact developmental phenotypes (77),
626 consistent with our own observations for *cpdR2* mutants of *A. tumefaciens* (Heindl et al.
627 unpublished results). If not CpdR2, the target could be a response regulator (RR-X) that
628 is thus far unrecognized to function in CtrA control (Fig. 6). In either case, one would
629 predict that the phosphorylated form of the response regulator is active for CtrA
630 inhibition, and that dephosphorylation by PdhS2 diminishes its inhibitory activity on
631 CtrA. Conversely, *pdhS2* mutants promote the strongly activated form of this response
632 regulator, inhibiting CtrA, derepressing *dgcB* expression and limiting motility, and in turn
633 driving cdGMP-responsive attachment. We have previously proposed additional direct
634 targets for the PdhS-type kinase DivJ as a means to explain the contradiction between
635 the essentiality of *divJ* and the non-essentiality of *divK* in *A. tumefaciens* (35). In that
636 work we also noted the possibility of DivJ directly targeting CtrA as observed *in vitro* for
637 *C. crescentus* DivJ. It is thus possible that both DivJ and PdhS2 in *A. tumefaciens* act

638 downstream of CckA, perhaps both through RR-X (Fig. 6), more directly influencing
639 CtrA (73). These models are currently being tested, but are more challenging due to the
640 essentiality of many of the regulatory components in this domain of the pathway for *A.*
641 *tumefaciens*, including DivJ itself.
642

643

MATERIALS AND METHODS

644

645 **Strains and plasmids.** Bacterial strains, plasmids, and oligonucleotides used in these
646 studies are listed in Tables S1 through S3. *A. tumefaciens* was routinely cultivated at
647 28°C in AT minimal medium plus 1% (w/v) glucose as a carbon source and 15 mM
648 (NH₄)₂SO₄ as a nitrogen source (ATGN), without exogenous FeSO₄ (74, 75). For biofilm
649 assays 22 μM FeSO₄ was included in the media. *E. coli* was routinely cultivated at 37°C
650 in lysogeny broth (LB). Antibiotics were used at the following concentrations (*A.*
651 *tumefaciens*/*E. coli*): ampicillin (100/100 μg·mL⁻¹), kanamycin (150/25 μg·mL⁻¹),
652 gentamicin (150/30 μg·mL⁻¹), spectinomycin (300/100 μg·mL⁻¹), and tetracycline (4/10
653 μg·mL⁻¹).

654 Non-polar, markerless deletion of *pdhS2* (Atu1888) in all genetic backgrounds
655 used in this work was accomplished using splicing by overlap extension (SOE)
656 polymerase chain reaction (PCR) followed by homologous recombination, as described
657 (35). Suicide plasmid pJEH040 carries an approximately 1 kb SOE deletion fragment of
658 *pdhS2* on a pNPTS138 vector backbone. pNPTS138 is a ColE1 plasmid and as such is
659 unable to replicate in *A. tumefaciens*. pJEH040 was delivered to recipient strains by
660 either transformation or conjugation followed by selection on ATGN plates
661 supplemented with 300 μg·mL⁻¹ Km, selecting for *A. tumefaciens* cells in which
662 pJEH040 had integrated at the chromosomal *pdhS2* locus by homologous
663 recombination. Recombinants were then grown overnight at 28°C in ATGN in the
664 absence of Km and plated the following day onto ATSN (ATGN with sucrose substituted
665 for glucose) agar plates to select for sucrose resistant (Suc^R) allelic replacement

666 candidates. After three days' growth at 28°C colonies were patched in parallel onto
667 ATGN Km and ATSN plates. Km^S Suc^R recombinants were then tested for the targeted
668 deletion by diagnostic PCR using primers external to the *pdhS2* locus (JEH100 and
669 JEH113) as well as internal primers (JEH85 and JEH87). Candidate colonies were
670 further streak purified and verified a second time by diagnostic PCR before being used
671 in downstream assays. Non-polar, markerless deletion of *dgcB* (Atu1691) in the $\Delta pleD$
672 and $\Delta pdhS2\Delta pleD$ genetic backgrounds was achieved using the above strategy with the
673 pNPTS138 derivative pJX802.

674 Site-directed mutagenesis of *pdhS2* was achieved using mutagenic primer pairs
675 JEH245/JEH246 (for generating the His271Ala allele, H271A) or JEH261/JEH262 (for
676 generating the Thr275Ala allele, T275A). Plasmid pJEH021 carrying the wild-type
677 *pdhS2* sequence was amplified by PCR using the above primer pairs. Following
678 amplification, reaction mixtures were treated with *DpnI* restriction endonuclease to
679 remove template plasmid and then transformed into TOP10 F' *E. coli* competent cells.
680 Purified plasmids from each transformation were sequenced and those containing the
681 desired mutations, pJEH091 for His271Ala and pJEH099 for Thr275Ala, were selected
682 for sub-cloning. pJEH091 and pJEH099 were digested with *NdeI* and *NheI* followed by
683 gel electrophoresis and purification of the resulting insert. Inserts were ligated into
684 similarly digested pSRKGm and transformed into competent *E. coli* TOP10 F' cells.
685 Purified plasmids from each transformation were sequenced to verify their identity. The
686 resulting plasmids, pJEH092 (H271A) and pJEH102 (T275A), were used to transform *A.*
687 *tumefaciens*. To generate a PdhS2 allele carrying both H271A and T275A mutations the
688 same steps were followed as above using plasmid pJEH091 as template with

689 mutagenic primers JEH261/JEH262. Site-directed mutagenesis of the second CtrA half-
690 site (5'-TTAA-3' → 5'-AATT-3') located 126 bp upstream of the start codon was
691 performed as above using mutagenic primer pairs USP073/USP074 and plasmid
692 pJX162 as template.

693 Translational fusions of full-length wild-type PdhS2 and DivJ to GFP were
694 constructed as follows. *pdhS2* and *divJ*, each lacking a stop codon were amplified by
695 PCR using primer pairs JEH65/JEH146 (*pdhS2*) and JEH147/JEH148 (*divJ*) with *A.*
696 *tumefaciens* strain C58 genomic DNA as template. Primer design for these
697 amplifications included 5' *NdeI* and 3' *NheI* restriction sites. The *gfpmut3* gene including
698 a 5' *NheI* site and a 3' *KpnI* site was amplified using primer pair JEH149/JEH150 and
699 pJZ383 as template. Amplicons were gel purified, ligated into pGEM-T Easy,
700 transformed into competent TOP10 F' *E. coli*, and eventually sequenced. The resulting
701 plasmids, pJEH052 (*pdhS2*), pJEH053 (*gfpmut3*), and pJEH054 (*divJ*) were digested
702 with either *NdeI* and *NheI* (pJEH052 and pJEH054) or *NheI* and *KpnI* (pJEH053).
703 Inserts were gel purified and used in a three-component ligation with *NdeI/KpnI*-
704 digested pSRKGm generating pJEH060 (PdhS2-GFP) and pJEH078 (DivJ-GFP).
705 Sequenced plasmids were used to transform *A. tumefaciens*.

706 Reporter gene fusion constructs included predicted promoter regions from
707 between 200 bp and 400 bp upstream of the indicated gene through the start codon.
708 Each upstream region was amplified by PCR using the primers listed in Table S3 using
709 *A. tumefaciens* genomic DNA as template. Amplicons were gel purified, ligated into
710 pGEM-T Easy, transformed into competent TOP10 F' *E. coli*, and eventually
711 sequenced. The resulting plasmids, pJEH113 (*ccrM*, Atu0794, promoter), pJEH115

712 (*ctrA*, Atu2434, promoter), and pJEH119 (*pdhS1*, Atu0614, promoter) were digested
713 with either *KpnI* and *HinDIII* (pJEH113 and pJEH119) or *KpnI* and *PstI* (pJEH115).
714 Inserts were gel purified and ligated with similarly cleaved pRA301 containing a
715 promoterless *E. coli lacZ* gene without its own ribosome binding site. The resulting
716 constructs (pJEH121, pJEH122, and pJEH124) carry *lacZ* translationally fused to the
717 start codon for each gene with transcription and translation driven by the fused
718 upstream region. pJEH121, pJEH122, and pJEH124 were used to transform *A.*
719 *tumefaciens* for subsequent beta-galactosidase assays.

720

721 **Static biofilm assays.** Overnight cultures in ATGN were sub-cultured in fresh ATGN to
722 an optical density at 600 nm (OD_{600}) of 0.1 and grown with aeration at 28°C until an
723 OD_{600} of 0.25-0.6. Cultures were diluted to OD_{600} of 0.05 and 3 mL were inoculated into
724 each of four wells in a 12-well plate. A single coverslip was placed vertically into each
725 well to submerge approximately half of each coverslip. Plates were incubated in a
726 humidified chamber at 28° for 48 h. Coverslips were removed from each well, rinsed
727 with water, and adherent biomass stained by 5 min immersion in a 0.1% (w/v) crystal
728 violet solution. Adsorbed crystal violet was solubilized by immersion in 1 mL 33% acetic
729 acid and the absorbance of this solution determined at 600 nm (A_{600}) on a Synergy HT
730 multi-detection microplate reader (Bio-Tek). Culture density for each sample was also
731 determined by measuring the OD_{600} of each culture. Data are typically presented as
732 A_{600}/OD_{600} ratios normalized to values obtained for the wild-type strain within each
733 experiment. ATGN was supplemented with antibiotics and 250 μ M IPTG as appropriate.
734 Final inoculations also included supplemental $FeSO_4$ (22 μ M). Each mutant was

735 evaluated in three independent experiments each of which contained three technical
736 replicates.

737

738 **Motility assays.** Wet mounts of exponentially growing cultures were observed under
739 brightfield optics using a Zeiss Axioskop 40 equipped with an AxioCam MRm
740 monochrome digital camera. Swim plates containing 0.3% agarose in ATGN,
741 supplemented with 1 mM IPTG and antibiotics when appropriate, were inoculated with a
742 single colony of the indicated strain at a central point and incubated for 7 days at 28°C.
743 Swim ring diameters were measured daily for seven days. Each experimental condition
744 was tested in three independent experiments containing three technical replicates.

745

746 **Microscopy.** Cell morphology and localization of PdhS2-GFP and DivJ-GFP was
747 evaluated using a Nikon E800 fluorescence microscope equipped with a Photometrics
748 Cascade cooled CCD camera. Overnight cultures were grown in ATGN with gentamicin
749 and 250 μ M IPTG. The following day each strain was sub-cultured to OD₆₀₀ 0.1 and
750 then grown at 28°C with aeration until \sim OD₆₀₀ 0.5-0.8. The culture (0.5 μ l) was
751 transferred to a 1% ATGN/agarose pad on a clean glass slide and a clean 22 x 22 mm
752 number 1.5 glass coverslip placed on top. Images were acquired using a 100X oil
753 immersion objective and phase contrast optics or epifluorescence with a FITC-HYQ
754 filter set (Nikon; excitation filter = 480/40 nm, dichromatic mirror = 505 nm, absorption
755 filter = 535/50 nm). Time-lapse microscopy utilized a Nikon Ti-E inverted fluorescence
756 microscope with a Plan Apo 60X/1.40 oil Ph3 DM objective, a DAPI/FITC/Cy3/Cy5 filter
757 cube, an Andor iXon3 885 EMCCD camera, and a Lumencor Spectra X solid state light

758 engine at 20% power. For time-lapse imaging agarose pads included 250 μ M IPTG and
759 coverslips were attached to the glass slide using a gas-permeable 1:1:1 mixture of
760 Vaseline, lanolin, and paraffin. Phase and fluorescence images were captured every 20
761 min for 8 h using a 60 ms (phase) or 2 s (fluorescence) exposure. Images were
762 analyzed using ImageJ (76-78).

763

764 **Transcriptional profiling.** Whole-genome transcriptional profiling using custom 60-
765 mer oligonucleotide microarrays was performed essentially as previously described
766 (79). Arrays were produced by Agilent Technologies, and consist of 8455 features that
767 represent 5338 predicted protein-encoding open reading frames, tRNA and rRNA
768 encoding genes, and 2,983 duplicate spots. Cultures of wild-type or the $\Delta pdhS2$ mutant
769 strain of *A. tumefaciens* strain C58 were grown overnight in ATGN to full turbidity and
770 then sub-cultured 1:150 into fresh ATGN for a second overnight growth. The following
771 morning a volume equivalent to 11 ml of OD₆₀₀ 0.6 was prepared for RNA extraction
772 using RNAprotect Bacteria Reagent (QIAGEN, Germantown, MD) following the
773 manufacturer's protocol. RNA was extracted from these samples using QIAGEN RNA
774 midipreps (QIAGEN, Germantown, MD) following the manufacturer's protocol. DNA
775 contamination was removed by DNase digestion using the TURBO DNA-free kit
776 (Ambion, Austin, TX) with the incubation time extended to two hours. First strand cDNA
777 synthesis was performed using Invitrogen SuperScript Indirect Labeling Kit, and cDNA
778 was purified on Qiagen QIAQuick columns. cDNA was labeled with AlexaFluor 555 and
779 647 dyes using Invitrogen SuperScript cDNA Labeling Kit, and repurified on QIAQuick
780 columns. cDNA was quantified on a NanoDrop spectrophotometer. Hybridization

781 reactions were performed using Agilent in situ Hybridization Kit Plus, boiled for 5 min at
782 95°C, applied to the printed arrays, and hybridized overnight at 65°C. Hybridized arrays
783 were washed with Agilent Wash Solutions 1 and 2, rinsed with acetonitrile, and
784 incubated in Agilent Stabilization and Drying Solution immediately prior to scanning the
785 arrays. Three independent biological replicates were performed, with one dye swap.
786 Hybridized arrays were scanned on a GenePix Scanner 4200 in the Center for
787 Genomics and Bioinformatics (CGB) at Indiana University. GenePix software was used
788 to define the borders of hybridized spots, subtract background, measure dye intensity at
789 each spot, and calculate the ratio of dye intensities for each spot. Analysis of the
790 scanned images was conducted using the LIMMA package in R/Bioconductor.
791 Background correction of the data was performed using the minimum method (80, 81).
792 The data was normalized within arrays with the LOESS method, and between arrays
793 with the quantile method. Statistical analysis was performed using linear model fitting
794 and empirical Bayesian analysis by least squares. Genes with significant *P* values (\leq
795 0.05) and with \log_2 ratios of ≥ 0.50 or ≤ -0.50 (representing a fold-change of ± 1.4) are
796 reported here. Expression data have been deposited in the Gene Expression Omnibus
797 (GEO) database at the National Center for Biotechnology Information (NCBI) under
798 accession number [GSE71267](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71267) (82).

799 β -galactosidase activity was measured using a modified protocol of Miller (83).
800 Cultures carrying transcriptional reporter plasmids were grown overnight in ATGN and
801 sub-cultured the following morning to OD₆₀₀ 0.15. Diluted cultures were grown at 28°C
802 with aeration until reaching mid-exponential growth. Between 100 and 300 μ L of
803 exponential phase culture was mixed with Z buffer (60 mM Na₂HPO₄, 40 mM NaH₂PO₄,

804 10 mM KCl, 1 mM MgSO₄, pH 7.0) to a final volume of 1 mL (volume of culture = f) plus
805 two drops 0.05% sodium dodecyl sulfate and 3 drops CHCl₃. The amount of culture
806 volume used was calibrated to generate reaction times between 15 minutes and two
807 hours for cultures with activity. 0.1 mL of a 4 mg·mL⁻¹ solution in Z buffer of the
808 colorimetric substrate 2-nitrophenyl β-D-galactopyranoside (ONPG) was added and the
809 time (t) required for the solution to turn yellow was recorded. The reaction was stopped
810 by addition of 1 M Na₂CO₃ and the absorbance at 420 nm (A₄₂₀) of each solution was
811 measured. Promoter activity is expressed in Miller units (MUs = [1000 x A_{420nm}]/[OD_{600nm}
812 x t x f]). Each mutant was tested in three independent experiments containing five
813 technical replicates.

814

815 **Protein stability assays.** Steady-state levels of CtrA were determined from stationary
816 phase cultures of wild-type, Δ*divK*, and Δ*pdhS2* strains of *A. tumefaciens*. Overnight
817 cultures of each strain were grown in TY broth at 28°C with aeration to an OD₆₀₀ > 1.
818 Two 1 mL aliquots were removed from each culture, pelleted by centrifugation (13,200 x
819 g, 2 min) and supernatants discarded. One of the resulting pellets was resuspended on
820 ice in 50 μL 100 mM Tris·HCl, pH 6.8, followed by 50 μL 2X SDS-PAGE loading buffer
821 (65.8 mM Tris·HCl, pH 6.8, 26.3% (v/v) glycerol, 2.1% (w/v) sodium dodecyl sulfate
822 (SDS), 0.01% (w/v) bromophenol blue), then stored frozen at -20°C. The second pellet
823 was resuspended in 100 μL 1X protein assay buffer (32.9 mM Tris·HCl, pH 6.8,
824 1% SDS), boiled 10 minutes, and used for protein concentration determination using the
825 Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), per manufacturer's
826 instructions. Frozen resuspended pellets were thawed on ice and β-mercaptoethanol

827 added to a final concentration of 5% prior to electrophoresis. Samples were normalized
828 for protein concentration and separated on a 12.5% SDS-polyacrylamide gel. Following
829 electrophoresis proteins were transferred to Immobilon-FL polyvinyl difluoride
830 membranes (EMD Millipore). Membranes were rinsed in 1X Tris-buffered saline (TBS;
831 50 mM Tris·HCl, pH 7.5, 150 mM NaCl) solution and air dried. Membranes were wetted
832 with MeOH and incubated in blocking buffer (1X TBS, 5% non-fat dairy milk [NFDM]) for
833 1 h at room temperature and then incubated overnight at 4°C with primary antibody
834 (1:5000 dilution of rabbit anti-CtrA from *C. crescentus*, anti-CtrA_{Cc}, in 1X TBS/5%
835 NFDM/0.2% Tween 20). The following day membranes were rinsed thoroughly with 1X
836 TBS/0.1% Tween 20 and incubated 1 h at room temperature with secondary antibody
837 (1:20,000 dilution of IRDye 800CW-conjugated goat anti-rabbit antibody (LI-COR) in 1X
838 TBS/5% NFDM/0.2% Tween 20/0.01% SDS). Membranes were rinsed thoroughly with
839 1X TBS/0.1% Tween 20 followed by 1X TBS alone and air dried in the dark. The
840 resulting blot was imaged using a LI-COR Odyssey Classic infrared imaging system.
841 Band intensities were quantified using the Odyssey Classic software.

842 Proteolytic turnover of CtrA was evaluated using translational shut-off assays.
843 Overnight cultures were grown in TY broth at 28°C with aeration. The following day
844 each strain was sub-cultured in fresh TY broth to an OD₆₀₀ 0.05 and incubated at 28°C
845 with aeration. To inhibit protein synthesis 90 µg·mL⁻¹ chloramphenicol was added to
846 each culture at OD₆₀₀ 0.5. Starting at the time of chloramphenicol addition 5 mL aliquots
847 were removed every 30 min for 3 h. Each aliquot was pelleted by centrifugation (5000 x
848 g, 10 min). Cleared supernatants were discarded and pellets resuspended to an OD₆₀₀
849 10.0 in Tris-Cl, (10 mM, pH 8.0). Resuspended pellets were mixed with 2X SDS-PAGE

850 loading buffer and stored frozen at -20°C. Levels of CtrA were determined by SDS-
851 PAGE and Western blotting as described above. Band intensities were quantified using
852 the Odyssey Classic software and normalized to the band intensity of CtrA from the
853 wild-type background at t = 0 min.

854

855 **Global cdGMP measurement.** Measurement of cdGMP levels was performed by liquid
856 chromatography, tandem mass spectrometry (LC-MS/MS) on a Quattro Premier XE
857 mass spectrometer coupled with an Acquity Ultra Performance LC system (Waters
858 Corporation), essentially as previously described (84). Concentrations of cdGMP in cell
859 samples were compared to chemically synthesized cdGMP (Axxora) dissolved in water
860 at concentrations of 250, 125, 62.5, 31.2, 15.6, 7.8, 3.9, and 1.9 nM to generate a
861 calibration curve. *A. tumefaciens* derivatives were grown in ATGN overnight at 28°C to
862 stationary phase. Culture densities were normalized after collecting cells by
863 centrifugation and then resuspension in the appropriate volume of ATGN. Cultures were
864 then pelleted by centrifugation and resuspended in ice-cold 250 µL extraction buffer
865 (methanol:acetonitrile:water, 40:40:20 + 0.1 N formic acid) and incubated for 30 min at -
866 20°C. Resuspensions were transferred to microcentrifuge tubes and pelleted (13,000 x
867 rpm, 5 min). 200 µL of the resulting supernatant was neutralized with 8 µL 15%
868 NH₄HCO₃. Neutralized samples were stored at -20°C. Prior to mass spectrometric
869 analysis, samples were vacuum centrifuged to remove extraction buffer and
870 resuspended in an equal volume of deionized water.

871

872

ACKNOWLEDGEMENTS

873 This project was supported by National Institutes of Health (NIH) grants GM080546 and
874 GM120337 (C.F.) and GM109259 (C.M.W.). J.E.H. was supported by a Ruth L.
875 Kirschstein National Research Service Award (1 F32 GM100601) from the NIH and the
876 Milton Lev Memorial Faculty Research Fund from University of the Sciences in
877 Philadelphia. The authors thank Peter Chien (U. Mass. Amherst) for generously
878 providing the CtrA_{Cc} antibody, and the Brun laboratory for access to and training on the
879 Nikon E800 microscope.

880

881

REFERENCES

- 882 1. **Kysela DT, Randich AM, Caccamo PD, Brun YV.** 2016. Diversity takes shape: understanding the
883 mechanistic and adaptive basis of bacterial morphology. *PLoS Biol* **14**:e1002565.
- 884 2. **Dworkin M.** 1985. *Developmental biology of the bacteria.* Benjamin/Cummings Pub. Co.,
885 Reading, Mass.
- 886 3. **Hajduk IV, Rodrigues CD, Harry EJ.** 2016. Connecting the dots of the bacterial cell cycle:
887 Coordinating chromosome replication and segregation with cell division. *Semin Cell Dev Biol*
888 **53**:2-9.
- 889 4. **Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM.** 1995. Microbial
890 biofilms. *Annu Rev Microbiol* **49**:711-45.
- 891 5. **Jonas K.** 2014. To divide or not to divide: control of the bacterial cell cycle by environmental
892 cues. *Curr Opin Microbiol* **18**:54-60.
- 893 6. **Brown PJ, de Pedro MA, Kysela DT, Van der Henst C, Kim J, De Bolle X, Fuqua C, Brun YV.** 2012.
894 Polar growth in the Alphaproteobacterial order Rhizobiales. *Proc Natl Acad Sci U S A* **109**:1697-
895 701.
- 896 7. **Zupan JR, Cameron TA, Anderson-Furgeson J, Zambryski PC.** 2013. Dynamic FtsA and FtsZ
897 localization and outer membrane alterations during polar growth and cell division in
898 *Agrobacterium tumefaciens*. *Proc Natl Acad Sci U S A* **110**:9060-5.
- 899 8. **Reuter SH, Shapiro L.** 1987. Asymmetric segregation of heat-shock proteins upon cell division in
900 *Caulobacter crescentus*. *J Mol Biol* **194**:653-62.
- 901 9. **Lindner AB, Madden R, Demarez A, Stewart EJ, Taddei F.** 2008. Asymmetric segregation of
902 protein aggregates is associated with cellular aging and rejuvenation. *Proc Natl Acad Sci U S A*
903 **105**:3076-81.
- 904 10. **Kysela DT, Brown PJ, Huang KC, Brun YV.** 2013. Biological consequences and advantages of
905 asymmetric bacterial growth. *Annu Rev Microbiol* **67**:417-35.
- 906 11. **Berne C, Ma X, Licata NA, Neves BR, Setayeshgar S, Brun YV, Dragnea B.** 2013. Physiochemical
907 properties of *Caulobacter crescentus* holdfast: a localized bacterial adhesive. *J Phys Chem B*
908 **117**:10492-503.
- 909 12. **Curtis PD, Brun YV.** 2010. Getting in the loop: regulation of development in *Caulobacter*
910 *crescentus*. *Microbiol Mol Biol Rev* **74**:13-41.
- 911 13. **Quon KC, Marczyński GT, Shapiro L.** 1996. Cell cycle control by an essential bacterial two-
912 component signal transduction protein. *Cell* **84**:83-93.
- 913 14. **Domian IJ, Reisenauer A, Shapiro L.** 1999. Feedback control of a master bacterial cell-cycle
914 regulator. *Proc Natl Acad Sci U S A* **96**:6648-53.
- 915 15. **Lasker K, Mann TH, Shapiro L.** 2016. An intracellular compass spatially coordinates cell cycle
916 modules in *Caulobacter crescentus*. *Curr Opin Microbiol* **33**:131-139.
- 917 16. **Jenal U, Fuchs T.** 1998. An essential protease involved in bacterial cell-cycle control. *EMBO J*
918 **17**:5658-69.
- 919 17. **Siam R, Marczyński GT.** 2000. Cell cycle regulator phosphorylation stimulates two distinct
920 modes of binding at a chromosome replication origin. *EMBO J* **19**:1138-47.
- 921 18. **Wheeler RT, Shapiro L.** 1999. Differential localization of two histidine kinases controlling
922 bacterial cell differentiation. *Mol Cell* **4**:683-94.
- 923 19. **Viollier PH, Sternheim N, Shapiro L.** 2002. Identification of a localization factor for the polar
924 positioning of bacterial structural and regulatory proteins. *Proc Natl Acad Sci U S A* **99**:13831-6.

- 925 20. **Hinz AJ, Larson DE, Smith CS, Brun YV.** 2003. The *Caulobacter crescentus* polar organelle
926 development protein PodJ is differentially localized and is required for polar targeting of the
927 PleC development regulator. *Mol Microbiol* **47**:929-41.
- 928 21. **Radhakrishnan SK, Thanbichler M, Viollier PH.** 2008. The dynamic interplay between a cell fate
929 determinant and a lysozyme homolog drives the asymmetric division cycle of *Caulobacter*
930 *crescentus*. *Genes Dev* **22**:212-25.
- 931 22. **Paul R, Jaeger T, Abel S, Wiederkehr I, Folcher M, Biondi EG, Laub MT, Jenal U.** 2008. Allosteric
932 regulation of histidine kinases by their cognate response regulator determines cell fate. *Cell*
933 **133**:452-61.
- 934 23. **Tropini C, Huang KC.** 2012. Interplay between the localization and kinetics of phosphorylation in
935 flagellar pole development of the bacterium *Caulobacter crescentus*. *PLoS Comput Biol*
936 **8**:e1002602.
- 937 24. **Subramanian K, Paul MR, Tyson JJ.** 2013. Potential role of a bistable histidine kinase switch in
938 the asymmetric division cycle of *Caulobacter crescentus*. *PLoS Comput Biol* **9**:e1003221.
- 939 25. **Subramanian K, Paul MR, Tyson JJ.** 2015. Dynamical localization of DivL and PleC in the
940 asymmetric division cycle of *Caulobacter crescentus*: a theoretical investigation of alternative
941 models. *PLoS Comput Biol* **11**:e1004348.
- 942 26. **Quon KC, Yang B, Domian IJ, Shapiro L, Marczyński GT.** 1998. Negative control of bacterial DNA
943 replication by a cell cycle regulatory protein that binds at the chromosome origin. *Proc Natl*
944 *Acad Sci U S A* **95**:120-5.
- 945 27. **Laub MT, Chen SL, Shapiro L, McAdams HH.** 2002. Genes directly controlled by CtrA, a master
946 regulator of the *Caulobacter* cell cycle. *Proc Natl Acad Sci U S A* **99**:4632-7.
- 947 28. **Laub MT, McAdams HH, Feldblyum T, Fraser CM, Shapiro L.** 2000. Global analysis of the genetic
948 network controlling a bacterial cell cycle. *Science* **290**:2144-8.
- 949 29. **Chen YE, Tsokos CG, Biondi EG, Perchuk BS, Laub MT.** 2009. Dynamics of two phosphorelays
950 controlling cell cycle progression in *Caulobacter crescentus*. *J Bacteriol* **191**:7417-29.
- 951 30. **Dubey BN, Lori C, Ozaki S, Fucile G, Plaza-Menacho I, Jenal U, Schirmer T.** 2016. Cyclic di-GMP
952 mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linking. *Sci Adv*
953 **2**:e1600823.
- 954 31. **Lori C, Ozaki S, Steiner S, Bohm R, Abel S, Dubey BN, Schirmer T, Hiller S, Jenal U.** 2015. Cyclic
955 di-GMP acts as a cell cycle oscillator to drive chromosome replication. *Nature* **523**:236-9.
- 956 32. **Tsokos CG, Perchuk BS, Laub MT.** 2011. A dynamic complex of signaling proteins uses polar
957 localization to regulate cell-fate asymmetry in *Caulobacter crescentus*. *Dev Cell* **20**:329-41.
- 958 33. **Childers WS, Xu Q, Mann TH, Mathews II, Blair JA, Deacon AM, Shapiro L.** 2014. Cell fate
959 regulation governed by a repurposed bacterial histidine kinase. *PLoS Biol* **12**:e1001979.
- 960 34. **Chen YE, Tropini C, Jonas K, Tsokos CG, Huang KC, Laub MT.** 2011. Spatial gradient of protein
961 phosphorylation underlies replicative asymmetry in a bacterium. *Proc Natl Acad Sci U S A*
962 **108**:1052-7.
- 963 35. **Kim J, Heindl JE, Fuqua C.** 2013. Coordination of division and development influences complex
964 multicellular behavior in *Agrobacterium tumefaciens*. *PLoS One* **8**:e56682.
- 965 36. **Curtis PD, Brun YV.** 2014. Identification of essential alphaproteobacterial genes reveals
966 operational variability in conserved developmental and cell cycle systems. *Mol Microbiol*
967 **93**:713-35.
- 968 37. **Romling U, Galperin MY, Gomelsky M.** 2013. Cyclic di-GMP: the first 25 years of a universal
969 bacterial second messenger. *Microbiol Mol Biol Rev* **77**:1-52.
- 970 38. **Gao R, Stock AM.** 2009. Biological insights from structures of two-component proteins. *Annu*
971 *Rev Microbiol* **63**:133-54.

- 972 39. **Huynh TN, Stewart V.** 2011. Negative control in two-component signal transduction by
973 transmitter phosphatase activity. *Mol Microbiol* **82**:275-86.
- 974 40. **Gao R, Stock AM.** 2017. Quantitative kinetic analyses of shutting off a two-component system.
975 *MBio* **8**.
- 976 41. **Hallez R, Bellefontaine AF, Letesson JJ, De Bolle X.** 2004. Morphological and functional
977 asymmetry in alpha-proteobacteria. *Trends Microbiol* **12**:361-5.
- 978 42. **Pini F, Frage B, Ferri L, De Nisco NJ, Mohapatra SS, Taddei L, Fioravanti A, Dewitte F, Galardini
979 M, Brilli M, Villeret V, Bazzicalupo M, Mengoni A, Walker GC, Becker A, Biondi EG.** 2013. The
980 DivJ, CbrA and PleC system controls DivK phosphorylation and symbiosis in *Sinorhizobium*
981 *meliloti*. *Mol Microbiol* **90**:54-71.
- 982 43. **Tsokos CG, Laub MT.** 2012. Polarity and cell fate asymmetry in *Caulobacter crescentus*. *Curr
983 Opin Microbiol* **15**:744-50.
- 984 44. **Laloux G, Jacobs-Wagner C.** 2014. How do bacteria localize proteins to the cell pole? *J Cell Sci*
985 **127**:11-9.
- 986 45. **Hallez R, Mignolet J, Van Mullem V, Wery M, Vandehaute J, Letesson JJ, Jacobs-Wagner C, De
987 Bolle X.** 2007. The asymmetric distribution of the essential histidine kinase PdhS indicates a
988 differentiation event in *Brucella abortus*. *EMBO J* **26**:1444-55.
- 989 46. **Lam H, Matroule JY, Jacobs-Wagner C.** 2003. The asymmetric spatial distribution of bacterial
990 signal transduction proteins coordinates cell cycle events. *Dev Cell* **5**:149-59.
- 991 47. **Ehrle HM, Guidry JT, Iacovetto R, Salisbury AK, Sandidge DJ, Bowman GR.** 2017. Polar
992 organizing protein PopZ is required for chromosome segregation in *Agrobacterium tumefaciens*.
993 *J Bacteriol* **199**.
- 994 48. **Kahng LS, Shapiro L.** 2001. The CcrM DNA methyltransferase of *Agrobacterium tumefaciens* is
995 essential, and its activity is cell cycle regulated. *J Bacteriol* **183**:3065-75.
- 996 49. **Brilli M, Fondi M, Fani R, Mengoni A, Ferri L, Bazzicalupo M, Biondi EG.** 2010. The diversity and
997 evolution of cell cycle regulation in alpha-proteobacteria: a comparative genomic analysis. *BMC
998 Syst Biol* **4**:52.
- 999 50. **Skerker JM, Shapiro L.** 2000. Identification and cell cycle control of a novel pilus system in
1000 *Caulobacter crescentus*. *EMBO J* **19**:3223-34.
- 1001 51. **Stephens CM, Zweiger G, Shapiro L.** 1995. Coordinate cell cycle control of a *Caulobacter* DNA
1002 methyltransferase and the flagellar genetic hierarchy. *J Bacteriol* **177**:1662-9.
- 1003 52. **Xu J, Kim J, Koestler BJ, Choi JH, Waters CM, Fuqua C.** 2013. Genetic analysis of *Agrobacterium
1004 tumefaciens* unipolar polysaccharide production reveals complex integrated control of the
1005 motile-to-sessile switch. *Mol Microbiol* **89**:929-48.
- 1006 53. **Zhou B, Schrader JM, Kalogeraki VS, Abeliuk E, Dinh CB, Pham JQ, Cui ZZ, Dill DL, McAdams
1007 HH, Shapiro L.** 2015. The global regulatory architecture of transcription during the *Caulobacter*
1008 cell cycle. *PLoS Genet* **11**:e1004831.
- 1009 54. **Heindl JE, Wang Y, Heckel BC, Mohari B, Feirer N, Fuqua C.** 2014. Mechanisms and regulation of
1010 surface interactions and biofilm formation in *Agrobacterium*. *Front Plant Sci* **5**:176.
- 1011 55. **Douglas CJ, Staneloni RJ, Rubin RA, Nester EW.** 1985. Identification and genetic analysis of an
1012 *Agrobacterium tumefaciens* chromosomal virulence region. *J Bacteriol* **161**:850-60.
- 1013 56. **Panis G, Murray SR, Viollier PH.** 2015. Versatility of global transcriptional regulators in alpha-
1014 Proteobacteria: from essential cell cycle control to ancillary functions. *FEMS Microbiol Rev*
1015 **39**:120-33.
- 1016 57. **De Bolle X, Crosson S, Matroule JY, Letesson JJ.** 2015. *Brucella abortus* cell cycle and infection
1017 are coordinated. *Trends Microbiol* **23**:812-21.

- 1018 58. **Matroule JY, Lam H, Burnette DT, Jacobs-Wagner C.** 2004. Cytokinesis monitoring during
1019 development; rapid pole-to-pole shuttling of a signaling protein by localized kinase and
1020 phosphatase in *Caulobacter*. *Cell* **118**:579-90.
- 1021 59. **Viollier PH, Sternheim N, Shapiro L.** 2002. A dynamically localized histidine kinase controls the
1022 asymmetric distribution of polar pili proteins. *EMBO J* **21**:4420-8.
- 1023 60. **Radhakrishnan SK, Pritchard S, Viollier PH.** 2010. Coupling prokaryotic cell fate and division
1024 control with a bifunctional and oscillating oxidoreductase homolog. *Dev Cell* **18**:90-101.
- 1025 61. **Pierce DL, O'Donnol DS, Allen RC, Javens JW, Quardokus EM, Brun YV.** 2006. Mutations in DivL
1026 and CckA rescue a *divJ* null mutant of *Caulobacter crescentus* by reducing the activity of CtrA. *J*
1027 *Bacteriol* **188**:2473-82.
- 1028 62. **Schallies KB, Sadowski C, Meng J, Chien P, Gibson KE.** 2015. *Sinorhizobium meliloti* CtrA stability
1029 is regulated in a CbrA-dependent manner that is influenced by CpdR1. *J Bacteriol* **197**:2139-49.
- 1030 63. **Jenal U, Reinders A, Lori C.** 2017. Cyclic di-GMP: second messenger extraordinaire. *Nat Rev*
1031 *Microbiol* **15**:271-284.
- 1032 64. **Aldridge P, Paul R, Goymier P, Rainey P, Jenal U.** 2003. Role of the GGDEF regulator PleD in
1033 polar development of *Caulobacter crescentus*. *Mol Microbiol* **47**:1695-708.
- 1034 65. **Lai TH, Kumagai Y, Hyodo M, Hayakawa Y, Rikihisa Y.** 2009. The *Anaplasma phagocytophilum*
1035 PleC histidine kinase and PleD diguanylate cyclase two-component system and role of cyclic di-
1036 GMP in host cell infection. *J Bacteriol* **191**:693-700.
- 1037 66. **Hug I, Deshpande S, Sprecher KS, Pfohl T, Jenal U.** 2017. Second messenger-mediated tactile
1038 response by a bacterial rotary motor. *Science* **358**:531-534.
- 1039 67. **Greene SE, Brilli M, Biondi EG, Komeili A.** 2012. Analysis of the CtrA pathway in
1040 *Magnetospirillum* reveals an ancestral role in motility in alphaproteobacteria. *J Bacteriol*
1041 **194**:2973-86.
- 1042 68. **Wang H, Ziesche L, Frank O, Michael V, Martin M, Petersen J, Schulz S, Wagner-Dobler I,**
1043 **Tomasch J.** 2014. The CtrA phosphorelay integrates differentiation and communication in the
1044 marine alphaproteobacterium *Dinoroseobacter shibae*. *BMC Genomics* **15**:130.
- 1045 69. **Zan J, Heindl JE, Liu Y, Fuqua C, Hill RT.** 2013. The CckA-ChpT-CtrA phosphorelay system is
1046 regulated by quorum sensing and controls flagellar motility in the marine sponge symbiont
1047 *Ruegeria* sp. KLH11. *PLoS One* **8**:e66346.
- 1048 70. **Quinones-Valles C, Sanchez-Osorio I, Martinez-Antonio A.** 2014. Dynamical modeling of the cell
1049 cycle and cell fate emergence in *Caulobacter crescentus*. *PLoS One* **9**:e111116.
- 1050 71. **Joshi KK, Berge M, Radhakrishnan SK, Viollier PH, Chien P.** 2015. An adaptor hierarchy
1051 regulates proteolysis during a bacterial cell cycle. *Cell* **163**:419-31.
- 1052 72. **Kobayashi H, De Nisco NJ, Chien P, Simmons LA, Walker GC.** 2009. *Sinorhizobium meliloti*
1053 CpdR1 is critical for co-ordinating cell cycle progression and the symbiotic chronic infection. *Mol*
1054 *Microbiol* **73**:586-600.
- 1055 73. **Wu J, Ohta N, Newton A.** 1998. An essential, multicomponent signal transduction pathway
1056 required for cell cycle regulation in *Caulobacter*. *Proc Natl Acad Sci U S A* **95**:1443-8.
- 1057 74. **Tempe J, Petit A, Holsters M, Montagu MV, Schell J.** 1977. Thermosensitive step associated
1058 with transfer of Ti plasmid during conjugation - possible relation to transformation in crown gall.
1059 *Proc. Natl. Acad. of Sci., USA* **74**:2848-2849.
- 1060 75. **Morton ER, Fuqua C.** 2012. Laboratory maintenance of *Agrobacterium*. *Curr Protoc Microbiol*
1061 **Chapter 1**:Unit3D 1.
- 1062 76. **Schneider CA, Rasband WS, Eliceiri KW.** 2012. NIH Image to ImageJ: 25 years of image analysis.
1063 *Nat Methods* **9**:671-5.

- 1064 77. **Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C,**
1065 **Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A.**
1066 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**:676-82.
- 1067 78. **Schindelin J, Rueden CT, Hiner MC, Eliceiri KW.** 2015. The ImageJ ecosystem: An open platform
1068 for biomedical image analysis. *Mol Reprod Dev* **82**:518-29.
- 1069 79. **Heindl JE, Hibbing ME, Xu J, Natarajan R, Buechlein AM, Fuqua C.** 2015. Discrete responses to
1070 limitation for iron and manganese in *Agrobacterium tumefaciens*: influence on attachment and
1071 biofilm formation. *J Bacteriol* **198**:816-29.
- 1072 80. **Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK.** 2015. limma powers differential
1073 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**:e47.
- 1074 81. R Core Team. 2016. R: A language and environment for statistical computing., *on* R Foundation
1075 for Statistical Computing. <https://www.R-project.org>. Accessed
- 1076 82. **Edgar R, Domrachev M, Lash AE.** 2002. Gene Expression Omnibus: NCBI gene expression and
1077 hybridization array data repository. *Nucleic Acids Res* **30**:207-10.
- 1078 83. **Miller JH.** 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor, New York.
- 1079 84. **Wang Y, Kim SH, Natarajan R, Heindl JE, Bruger EL, Waters CM, Michael AJ, Fuqua C.** 2016.
1080 Spermidine inversely influences surface interactions and planktonic growth in *Agrobacterium*
1081 *tumefaciens*. *J Bacteriol* **198**:2682-91.

1082

1083

1084 **Tables**

1085

1086 **Table 1. Promoter activity of selected known and predicted CtrA-dependent**

1087 **promoters.^a**

Strain	Promoter source organism	Promoter	Activity (%WT ± SE)
WT	<i>C. crescentus</i>	<i>ccrM</i>	100 ± 1
		<i>ctrA</i>	100 ± 2
		<i>pilA</i>	100 ± 1
	<i>A. tumefaciens</i>	<i>ccrM</i>	100 ± 1
		<i>ctrA</i>	101 ± 1
		<i>pdhS1</i>	100 ± 1
		<i>dgcB</i>	100 ± 12
	Atu3318	104 ± 25	
$\Delta pdhS2$	<i>C. crescentus</i>	<i>ccrM</i>	109 ± 12
		<i>ctrA</i>	82 ± 4 ^b
		<i>pilA</i>	85 ± 2 ^b
	<i>A. tumefaciens</i>	<i>ccrM</i>	106 ± 2 ^b
		<i>ctrA</i>	84 ± 3 ^b
		<i>pdhS1</i>	119 ± 3 ^b
		<i>dgcB</i>	201 ± 26 ^b
		<i>dgcB*</i>	156 ± 1 ^c
	Atu3318	352 ± 13 ^b	
$\Delta divK$	<i>C. crescentus</i>	<i>ccrM</i>	140 ± 6 ^b
		<i>ctrA</i>	132 ± 4 ^b
		<i>pilA</i>	99 ± 3
	<i>A. tumefaciens</i>	<i>ccrM</i>	116 ± 3 ^b
		<i>ctrA</i>	117 ± 2 ^b
		<i>pdhS1</i>	90 ± 1 ^b
		<i>dgcB</i>	68 ± 1 ^b
		<i>dgcB*</i>	56 ± 1 ^c
	Atu3318	62 ± 1 ^b	

1088

1089 ^a Promoter activity was measured as β -galactosidase activity of cell lysates from strains

1090 carrying either transcriptional (for *C. crescentus* promoters) or translational (for *A.*

1091 *tumefaciens* promoters) fusions of the indicated promoter regions to the *E. coli lacZ*

1092 gene. Activity for each promoter was normalized to activity in lysates from wild-type
1093 cells carrying the identical promoter. N = 9.

1094

1095 ^b $P < 0.05$ compared to WT value using Student's *t* test.

1096

1097 ^c *dgcB** indicates the same promoter region as for *dgcB* with mutation of the second
1098 CtrA half-site at -126 from 5'-TTAA-3' to 5'-AATT-3'. $P < 0.001$ compared to value for
1099 wild-type *dgcB* promoter in same strain background using Student's *t* test.

1100

1101 **Table 2. Differentially-regulated genes in the absence of *pdhS2*.^a**

Locus	Gene	Product ^b	log ₂ FC	CtrA binding site (+/-) ^c	CtrA half-site (+/-) ^c	Present in other PdhS arrays? ^d
Atu0461	-	<i>phage tail protein/type VI secretion system component</i>	2.42	(+) Atu8182 ^e	+	no
Atu0227	-	tRNA-Leu	2.15	-	+	no
Atu5167	<i>avhB6</i>	type IV secretion protein	2.01	-	+	no
Atu2490	<i>asd</i>	aspartate semialdehyde dehydrogenase	1.93	-	+	no
Atu3318	-	LuxR family transcriptional regulator	1.84	+	+	no
Atu1471	<i>rluC</i>	ribosomal large subunit pseudouridine synthase C	1.84	-	+	no
Atu3755	<i>purK</i>	phosphoribosylaminoimidazole carboxylase ATPase subunit	1.70	-	+	no
Atu3606	<i>ftsE</i>	cell division ATP-binding protein	1.63	+	+	no
Atu1791	-	ABC transporter, membrane spanning protein (sugar)	1.55	-	+	no
Atu3572	-	XRE family transcriptional regulator	1.52	+	+	yes
Atu2217	-	<i>hypothetical protein</i>	1.52	-	+	no
Atu5119	<i>phoB</i>	two component response regulator	1.48	-	-	no
Atu3031	-	<i>hypothetical protein</i>	1.46	-	-	no
Atu1886	-	<i>DNA glycosylase</i>	1.41	-	-	no
Atu1964	-	tRNA-Trp	1.40	+	+	no
Atu1301	-	<i>Nudix hydrolase</i>	1.39	-	+	no
Atu3610	-	cation transporter	1.34	-	-	no
Atu6048	-	<i>RNA helicase</i>	1.32	-	+	no
Atu1691	<i>dgcB</i>	GGDEF family protein	1.32	+	+	no
Atu1887	<i>exol</i>	succinoglycan biosynthesis protein	1.30	+	+	no
Atu1134	-	<i>lysyl-phosphatidylglycerol synthase</i>	1.30	-	-	no
Atu2665	-	MarR family transcriptional regulator	1.27	-	+	no
Atu2204	-	<i>hypothetical protein</i>	1.25	-	+	no
Atu0540	-	<i>hypothetical protein</i>	1.25	-	-	no
Atu4856	-	nucleotidyltransferase	-1.21	-	-	no
Atu4347	<i>tae</i>	type VI secreted effector	-1.23	(+) Atu4344	-	no
Atu4055	<i>exoK</i>	endo-1,3-1,4-beta-glycanase	-1.28	(+) Atu4056	+	yes
Atu4345	<i>tssD</i>	type VI secretion needle tube protein	-1.29	(+) Atu4344	+	no
Atu5091	<i>rcdB</i>	curdlan synthesis protein	-1.32	+	+	no
Atu4357	-	<i>transglutaminase-like Cys protease</i>	-1.34	-	+	yes

Atu0343	<i>barA</i>	two component sensor kinase/response regulator hybrid	-1.37	-	-	no
Atu4053	<i>exoA</i>	succinoglycan biosynthesis protein	-1.42	(+) Atu4056	+	yes
Atu4056	<i>exoH</i>	succinoglycan biosynthesis protein	-1.42	+	+	yes
Atu3564	<i>exsH</i>	endo-1,3-1,4-beta-glycanase	-1.46	-	-	no
Atu3541	-	<i>transglutaminase-like Cys protease</i>	-1.51	-	+	no
Atu4627	-	<i>hypothetical protein</i>	-1.56	-	-	no
Atu4049	<i>exoP</i>	exopolysaccharide polymerization/transport protein	-1.64	(+) Atu4056	+	no
Atu1469	-	<i>hypothetical protein</i>	-1.80	+	+	no
Atu4050	<i>exoN</i>	UTP-glucose-1-phosphate uridylyltransferase	-1.82	(+) Atu4056	+	yes

1102

1103 ^a Gene expression was compared between WT and $\Delta pdhS2$ strains using whole-
 1104 genome microarrays. Genes were defined as differentially regulated when the following
 1105 conditions were met: $\log_2 FC \geq 0.50$ OR $\log_2 FC \leq -0.50$, AND $P < 0.050$, AND $Q < 0.10$.

1106

1107 ^b Predicted functions of hypothetical proteins, if available, are italicized.

1108

1109 ^c Intergenic regions 500 nt upstream and 100 nt downstream of start codon for each
 1110 gene (or operon, if applicable) was scanned for possible CtrA binding sites, as
 1111 described in the text.

1112

1113 ^d Results were compared with previously published *S. meliloti cbrA* and *divJ* microarrays
 1114 and *C. crescentus divJ* and *pleC* microarrays, as described in the text.

1115

1116 ^e (+) with Atu number indicates that the putative CtrA box is located in the first gene of a
 1117 predicted operon

1118 **Figure Legends**

1119 **Figure 1. The PdhS kinases of *C. crescentus* and *A. tumefaciens* differentially**

1120 **localize and affect phenotypic outputs through response regulators DivK, PleD,**

1121 **and CtrA.** (A) Cartoon model of known localization of the namesake PdhS kinases from

1122 *C. crescentus*, PleC and DivJ, and three PdhS kinases from *A. tumefaciens*, PdhS1,

1123 PdhS2, and DivJ. Kinases represented as colored ovals with black border

1124 experimentally localize to the indicated poles. The PleC oval without a border has not

1125 been experimentally demonstrated to localize in *A. tumefaciens*. As a result of this

1126 localization phosphorylation status of direct PdhS kinase targets, DivK and PleD, and

1127 the indirect target, CtrA, may be differentially affected. (B) Multiple sequence alignment

1128 of the HisKA domain from the PdhS kinases of *C. crescentus* and *A. tumefaciens*.

1129 Sequences were aligned using the Clustal Omega web service hosted by the European

1130 Molecular Biology Laboratory (EMBL)-European Bioinformatics Institute. The four PdhS

1131 kinases from *A. tumefaciens* plus PleC and DivJ from *C. crescentus* were included. Also

1132 included are two additional predicted PdhS kinases, CC_0652 and CC_1062, from *C.*

1133 *crescentus*. The EnvZ sensor kinase is included for comparison. Yellow highlighting

1134 indicates residues that define the PdhS kinases. The conserved histidine and threonine

1135 residues mutated in this work are in bold.

1136

1137 **Figure 2. Evaluation of roles for PdhS2 kinase and phosphatase activities and**

1138 **genetic interactions with *divK*.** (A) The ability of plasmid-borne wild-type PdhS2 (p-

1139 *pdhS2*), the kinase-null allele (p-*pdhS2*, K⁻P⁺), or the phosphatase-null allele (p-*pdhS2*,

1140 K⁺P⁻) to complement the Δ *pdhS2* biofilm formation (black bars) and swimming motility

1141 (white bars) phenotypes was evaluated using P_{lac} -driven expression of each allele.
1142 Static biofilm formation was measured after 48 h (black bars) and swim ring diameter
1143 after 7 days (white bars). Adherent biomass on PVC coverslips was determined by
1144 adsorption of crystal violet. Crystal violet was then solubilized and $A_{600\text{ nm}}$ values were
1145 normalized to culture density (OD_{600}). Data are the mean of three independent
1146 experiments each of which contained three technical replicates ($N = 3$). Swim ring
1147 diameters were measured after single-colony inoculation into low density swim agar and
1148 incubation at room temperature. Data are the mean of nine independent experiments (N
1149 = 9). (B) Biofilm formation (black bars) and swimming motility (white bars) were
1150 evaluated in the indicated strains. Experiments were performed and data analyzed as
1151 described for (A) above. (C) The effect of plasmid-borne wild-type PdhS2 ($p\text{-}pdhS2$), the
1152 kinase-null allele ($p\text{-}pdhS2$ (K^{P^+})), or the phosphatase-null allele ($p\text{-}pdhS2$ (K^{P^-})) on
1153 biofilm formation (black bars) and swimming motility (white bars) when expressed from
1154 the P_{lac} promoter in the $\Delta divK$ mutant background was evaluated as in (A) and (B)
1155 above. For presentation all data are normalized to WT and expressed as %WT \pm
1156 standard error of the mean (S.E.). ^(a) = $P < 0.05$ compared to wild-type strain or wild-
1157 type strain carrying empty vector. ^(b) = $P < 0.05$ compared to $\Delta pdhS2$ strain carrying
1158 empty vector (A), or compared to the $\Delta pdhS2$ mutant strain (B), or compared to the
1159 $\Delta divK$ strain carrying empty vector (C). Statistical significance was determined using
1160 Student's t test.

1161

1162 **Figure 3. PdhS2 and DivJ are polarly localized in *A. tumefaciens*.** Time-lapse
1163 microscopy of a C-terminal green fluorescent protein fusions to PdhS2 (A) and DivJ (B).

1164 Overlaid phase and fluorescent images, acquired sequentially on Nikon E800
1165 fluorescence microscope with a CCD camera using the 100 X objective. Time between
1166 panels is 40 minutes. To the right of each image is a cartoon interpretation of the image.

1167

1168 **Figure 4. PdhS2 impacts CtrA abundance but not turnover kinetics.** (A) Steady-
1169 state CtrA levels in indicated strains as determined via SDS-PAGE followed by
1170 immunoblotting with rabbit anti-CtrA_{Cc} primary and IRDye 800CW-conjugated goat anti-
1171 rabbit secondary antibodies. (B) Proteolytic turnover of CtrA following translational
1172 arrest with chloramphenicol. Aliquots were removed at the indicated time points, lysed,
1173 and stored frozen at -20 °C. CtrA levels were then determined via SDS-PAGE followed
1174 by immunoblotting, as described for (A) above. Blots were imaged using an LI-COR
1175 Odyssey Classic infrared imaging system and band intensities quantified with the
1176 Odyssey Classic software. Protein concentrations for each sample were normalized to
1177 optical density prior to electrophoresis.

1178

1179 **Figure 5. PdhS2 intersects with the activity of multiple diguanylate cyclases.** (A)
1180 Biofilm formation was quantified for the wild-type (WT) and indicated mutant strains as
1181 described in Figure 2. PleD, DgcA, DgcB have demonstrated *in vivo* diguanylate
1182 cyclase enzymatic activity. Thus far conditions under which DgcC is active have yet to
1183 be identified. $P < 0.05$ compared to WT (^a), $\Delta pdhS2$ (^b), or corresponding diguanylate
1184 cyclase (^c). (B) The effect on biofilm formation of plasmid-borne expression of wild-type
1185 *dgcB* (p-*dgcB*) or a catalytic mutant allele of *dgcB* (p-*dgcB*^{*}) was evaluated. Expression

1186 of each *dgcB* allele was driven by the P_{lac} promoter. Biofilm formation was evaluated as
1187 described in Figure 2. (*) = $P < 0.05$ compared to vector alone.

1188

1189 **Figure 6. An alternative model for PdhS2 regulation of CtrA activity.** Our data are
1190 consistent with PdhS2 intersecting the DivK-CtrA regulatory pathway at one of two
1191 points. (Pathway A) Canonical genetic model with PdhS2 interacting with DivK. The
1192 phosphorylation status of DivK then modulates CtrA activity through the CckA-ChpT-
1193 CtrA axis. (Pathway B) DivK-independent model of CtrA regulation by PdhS2 through
1194 an unidentified response regulator, RR-X. Both routes to regulation of CtrA activity
1195 ultimately affect the phosphorylation status of CtrA, affecting occupancy at CtrA-
1196 regulated promoters, and finally leading to inverse regulation of attachment (primarily
1197 through cdGMP pools) and separately motility. Regulatory proteins: Blue text; histidine
1198 kinases; orange text, histidine phosphotransferase (Hpt); green text, response
1199 regulators. RR-X indicates a putative response regulator, yet to be identified.

1200

SUPPLEMENTARY MATERIAL

Reciprocal control of motility and biofilm formation by the PdhS2

two-component sensor kinase of *Agrobacterium tumefaciens*

Jason E. Heindl, Daniel Crosby, Sukhdev Brar, Tiyan Singletary, Daniel Merenich, Aaron M. Buechlein, Justin L. Eagan, Eric L. Bruger, Christopher M. Waters and Clay Fuqua

Running title: *Agrobacterium PdhS2 regulates motility and biofilms*

1) Supplementary Figures – S1-S10

2) Supplementary Figure Legends

3) Supplementary Tables – S1-S3

4) Supplementary References

Figure S1. A combined kinase- and phosphatase-null PdhS2 mutant allele has little effect on biofilm formation or swimming motility. The ability of plasmid-borne expression of a kinase- and phosphatase- null allele of *pdhS2* (*p-pdhS2* (K⁻P⁻)) to complement the $\Delta pdhS2$ phenotypes was compared against the wild-type *pdhS2* allele (*p-pdhS2*). Biofilm formation (black bars) and swimming motility (white bars) were evaluated as in Figure 2. (a) = $P < 0.05$ compared to the wild-type background with vector only; (b) = $P < 0.05$ compared to the $\Delta pdhS2$ background with vector only. Statistical significance was determined using Student's *t* test.

Figure S2. Morphology of WT, $\Delta divK$, $\Delta pdhS2$, and $\Delta divK \Delta pdhS2$ strains. Strains were grown to exponential phase in ATGN. Aliquots of cells were placed on top of an ATGN/1% agarose pad and imaged using phase contrast microscopy. (A), WT; (B) $\Delta divK$; (C) $\Delta pdhS2$; (D) $\Delta divK \Delta pdhS2$. Representative images are shown. Scale bar = 2 μm .

Figure S3. A kinase-locked allele of CckA fails to suppress the PdhS2-dependent biofilm phenotype. Biofilm formation was evaluated in the indicated strains as described in Figure 2. (*) = $P < 0.05$ compared to background strain carrying vector alone. Statistical significance was determined using Student's *t* test.

Figure S4. A kinase-locked allele of CckA fails to suppress the PdhS2-dependent swimming motility phenotype. Swimming motility was evaluated in the indicated

strains as described in Figure 2. (*) = $P < 0.001$ compared to background strain carrying vector alone. Statistical significance was determined using Student's *t* test.

Figure S5. Predicted CtrA-dependent promoters bearing one or more CtrA binding motifs. Upstream regions from genes whose expression is increased (red) or decreased (black) in the $\Delta pdhS2$ mutant background relative to the wild-type background (microarray or *lacZ* fusion data). Predicted CtrA binding sites, as defined in the main text, are indicated. For genes in operons, the most upstream gene that has a predicted CtrA box is shown, even if this upstream gene did not make the expression cutoff for Table 2 (e.g. Atu4344 and Atu 8282). Only those genes with a predicted full CtrA binding site are shown.

Figure S6. PdhS2 regulation of swimming motility is independent of diguanylate cyclase activity. Swimming motility of the wild-type (WT) and indicated mutant strains was evaluated as described in Figure 2. $P < 0.05$ compared to WT (^a), $\Delta pdhS2$ (^b), or corresponding diguanylate cyclase (^c).

Figure S7. Loss of *pdhS2* enhances biofilm formation in the absence of both *dgcB* and *pleD*. Biofilm formation and swimming motility was evaluated in the wild-type (WT) and indicated mutant strains as described in Figure 2. (*) = $P < 0.05$ compared to the wild-type background. Statistical significance was determined using Student's *t* test.

Figure S8. PdhS2 does not affect global levels of cyclic-di-GMP. Cyclic-di-GMP

levels were measured in whole cell extracts from equivalent ODs of the indicated strains. Data are from three independent experiments (N = 3).

Figure S9. A catalytically inactive DgcB does not affect swimming motility. The

effect on swimming motility of plasmid-borne expression of wild-type *dgcB* (*p-dgcB*) or a catalytic mutant allele of *dgcB* (*p-dgcB**) was evaluated. Expression of each *dgcB* allele was driven by the *P_{lac}* promoter. Biofilm formation was evaluated as described in Figure 2. (*) = $P < 0.05$ compared to vector alone.

Figure S10. The unipolar polysaccharide is required for PdhS2-dependent biofilm

formation. (A) Biofilm formation was evaluated in the presence (+) or absence (-) of

pdhS2 in combination with the indicated polysaccharides. WT = wild-type, Cel⁻ =

cellulose mutant, ChvAB⁻ = cyclic- β -glucan mutant, CrdS⁻ = curdlan mutant, ExoA⁻ =

succinoglycan mutant, UPP⁻ = unipolar polysaccharide mutant, EPS⁻ = mutant lacking all

of the above polysaccharides. (B) Swimming motility was evaluated in the same strains

as in (A). (*) = $P < 0.05$ compared to background strain. Statistical significance was

determined using Student's *t* test.

Figure S1




Figure S2







Figure S3





Figure S4



CtrA Binding Site Consensus

TTAANNNNNGTTAAC




Figure S6




Figure S7




Figure S8




Figure S9




Figure S10A




Figure S10B




Table S1. Strains used in this study

Species	Strain	Relevant Characteristics	Source
<i>A. tumefaciens</i>	C58	Nopaline type strain, pAtC58, pTiC58	(1)
<i>A. tumefaciens</i>	C58-JE001	$\Delta dgcB \Delta pdhS2 \Delta pleD$ ($\Delta Atu1691$ $\Delta Atu1888 \Delta Atu1297$)	This study
<i>A. tumefaciens</i>	C58-JE002	$\Delta dgcB \Delta pleD$ ($\Delta Atu1691 \Delta Atu1297$)	This study
<i>A. tumefaciens</i>	C58-JEH076	$\Delta pdhS2$ ($\Delta Atu1888$)	(2)
<i>A. tumefaciens</i>	C58-JEH128	$\Delta pdhS2 \Delta pleD$ ($\Delta Atu1888 \Delta Atu1297$)	This study
<i>A. tumefaciens</i>	C58-JEH130	$\Delta pdhS2 \Delta dgcA$ ($\Delta Atu1888 \Delta Atu1257$)	This study
<i>A. tumefaciens</i>	C58-JEH131	$\Delta pdhS2 \Delta dgcB$ ($\Delta Atu1888 \Delta Atu1691$)	This study
<i>A. tumefaciens</i>	C58-JEH132	$\Delta pdhS2 \Delta dgcC$ ($\Delta Atu1888 \Delta Atu2179$)	This study
<i>A. tumefaciens</i>	C58-JEH146	$\Delta pdhS2 \Delta crdS \Delta chvAB \Delta cel \Delta upp$ $\Delta exoA$ ($\Delta Atu1888 \Delta Atu3055-3057$ $\Delta Atu2728-2730 \Delta Atu3302-8187$ $\Delta Atu1235-1240 \Delta Atu4053$)	This study
<i>A. tumefaciens</i>	C58-JEH147	$\Delta pdhS2 \Delta upp$ ($\Delta Atu1888 \Delta Atu1235-1240$)	This study

<i>A. tumefaciens</i>	C58-JEH148	$\Delta pdhS2 \Delta cel$ ($\Delta Atu1888 \Delta Atu3302-8187$)	This study
<i>A. tumefaciens</i>	C58-JEH149	$\Delta pdhS2 \Delta crdS$ ($\Delta Atu1888 \Delta Atu3055-3057$)	This study
<i>A. tumefaciens</i>	C58-JEH150	$\Delta pdhS2 \Delta chvAB$ ($\Delta Atu1888 \Delta Atu2728-Atu2730$)	This study
<i>A. tumefaciens</i>	C58-JEH151	$\Delta pdhS2 \Delta exoA$ ($\Delta Atu1888 \Delta Atu4053$)	This study
<i>A. tumefaciens</i>	C58-JEH153	$\Delta divK \Delta pdhS2$ ($\Delta Atu1296 \Delta Atu1888$)	This study
<i>A. tumefaciens</i>	C58-JW7	$\Delta divK$ ($\Delta Atu1296$)	(2)
<i>A. tumefaciens</i>	C58-JW8	$\Delta pleD$ ($\Delta Atu1297$)	(2)
<i>A. tumefaciens</i>	C58-JX100	$\Delta crdS$ ($\Delta Atu3055-3057$)	(3)
<i>A. tumefaciens</i>	C58-JX101	$\Delta chvAB$ ($\Delta Atu2728-2730$)	(3)
<i>A. tumefaciens</i>	C58-JX102	Δcel ($\Delta Atu3302-8187$)	(3)
<i>A. tumefaciens</i>	C58-JX111	$\Delta crdS \Delta chvAB \Delta cel \Delta upp \Delta exoA$ ($\Delta Atu3055-3057 \Delta Atu2728-2730 \Delta Atu3302-8187 \Delta Atu1235-1240 \Delta Atu4053$; "EPS-")	(3)
<i>A. tumefaciens</i>	C58-JX125	$\Delta dgcA$ ($\Delta Atu1257$)	(4)
<i>A. tumefaciens</i>	C58-JX187	$\Delta dgcB$ ($\Delta Atu1691$)	(4)

<i>A. tumefaciens</i>	C58-MLL2 A	Δ <i>exoA</i> (Δ Atu4053)	(5)
<i>A. tumefaciens</i>	C58-PMM26	Δ <i>upp</i> (Δ Atu1235-1240)	(3)
<i>A. tumefaciens</i>	C58-YW010	Δ <i>dgcC</i> (Δ Atu2179)	(4)
<i>E. coli</i>	S17-1 λ <i>pir</i>	RK2 <i>tra</i> regulon, <i>pir</i> , host for <i>pir</i> -dependent plasmids	(6)
<i>E. coli</i>	TOP10 F'	F' <i>{lacI^q Tn10 (Tet^R)}</i> <i>mcrA</i> Δ (<i>mrr-hsdRMS-mcrBC</i>) Φ 80 <i>lacZ</i> Δ M15 Δ <i>lacX74</i> <i>recA1</i> <i>araD139</i> Δ (<i>ara-leu</i>)7697 <i>galU</i> <i>rpsL</i> <i>endA1</i> <i>nupG</i>	Thermo Fisher Scientific

Table S2. Plasmids used in this study

Plasmid name	Relevant characteristics	Source
pGEM-T Easy	PCR cloning vector; Amp ^R	Promega
<i>placZ</i> /290	Broad host range plasmid carrying promoterless <i>lacZ</i> for transcriptional fusions; Tet ^R	(7)
pNPTS138	ColE1 origin; <i>sacB</i> ; Km ^R	gift of M. Alley
pRA301	Broad host range plasmid carrying promoterless <i>lacZ</i> for translational fusions; Spec ^R	(8)
pSRKGm	Broad host range vector containing P _{lac} ; <i>lacI^q</i> ; <i>lacZα⁺</i> ; Gm ^R	(9)
<i>pctrA</i> 290	<i>placZ</i> /290 derivative with <i>C. crescentus ctrA</i> promoter	(10)
pDC001	pGEM-T Easy with full-length <i>pdhS2</i> ^(CA811-812GC, A823G) (<i>PdhS2</i> ^{His271A,Thr275Ala} mutant)	This study

pDC002	pSRKGm with full-length <i>pdhS2</i> ^(CA811-812GC, A823G) (PdhS2 ^{His271A,Thr275Ala} mutant)	This study
pGZ22	<i>placZ</i> /290 derivative with <i>C. crescentus ccrM</i> promoter	(11)
pJEH010	pSRKGm with full-length wild-type <i>cckA</i>	(2)
pJEH021	pGEM-T Easy with full- length <i>pdhS2</i>	(2)
pJEH026	pSRKGm with full-length <i>pdhS2</i>	(2)
pJEH030	pSRKGm with full-length Y674D <i>cckA</i> allele	(2)
pJEH040	pNPTS138 derivative with <i>pdhS2</i> SOE deletion fragment	(2)
pJEH052	pGEM-T Easy with <i>pdhS2</i> lacking a stop codon	This study
pJEH053	pGEM-T Easy with <i>gfpmut3</i>	This study

pJEH054	pGEM-T Easy with <i>divJ</i> lacking a stop codon	This study
pJEH060	pSRKGm with a <i>pdhS2::gfpmut3</i> translational fusion	This study
pJEH078	pSRKGm with a <i>divJ::gfpmut3</i> translational fusion	This study
pJEH091	pGEM-T Easy with full-length <i>pdhS2</i> ^(CA811-812GC) (PdhS2 ^{His271Ala} mutant)	This study
pJEH092	pSRKGm with full-length <i>pdhS2</i> ^(CA811-812GC) (PdhS2 ^{His271Ala} mutant)	This study
pJEH099	pGEM-T Easy with full-length <i>pdhS2</i> ^(A823G) (PdhS2 ^{Thr275Ala} mutant)	This study
pJEH102	pSRKGm with full-length <i>pdhS2</i> ^(A823G) (PdhS2 ^{Thr275Ala} mutant)	This study
pJEH113	pGEM-T Easy with A. <i>tumefaciens ccrM</i> promoter	This study

pJEH115	pGEM-T Easy with <i>A. tumefaciens ctrA</i> promoter	This study
pJEH119	pGEM-T Easy with <i>A. tumefaciens pdhS1</i> promoter	This study
pJEH121	pRA301 with <i>A. tumefaciens ccrM</i> promoter	This study
pJEH122	pRA301 with <i>A. tumefaciens ctrA</i> promoter	This study
pJEH124	pRA301 with <i>A. tumefaciens pdhS1</i> promoter	This study
pJEH133	pRA301 with mutated <i>A. tumefaciens dgcB</i> promoter	This study
pJS70	<i>placZ/290</i> derivative with <i>C. crescentus pilA</i> promoter	(12)
pJX158	pRA301 with <i>A. tumefaciens Atu3318</i> promoter	(4)

pJX162	pRA301 with <i>A. tumefaciens</i> <i>dgcB</i> promoter	(4)
pJX520	pSRKGm with full-length <i>dgcB</i>	(4)
pJX521	pSRKGm with full-length <i>dgcB</i> ^{A767C, A770C} (<i>DgcB</i> ^{EE256-257AA} mutant)	(4)
pJX802	pNPTS138 derivative with <i>dgcB</i> SOE deletion fragment	(4)
pJZ383	pPZP201 derivative with <i>P</i> _{tac} :: <i>gfpmut3</i> ; Spec ^R	(13)

Table S3. Primers used in this study

Primer	Sequence (5' – 3')	Use
JEH65	GAAGAA <u>CATATGAGT</u> AAAAGCGTCAG CA	cloning <i>pdhS2</i> with NdeI site
JEH85	GATTTGCGCGGATCCCTTCGA	Internal primer for <i>pdhS2</i> locus
JEH87	GAGCAGATGCTGGCCGGA	Internal primer for <i>pdhS2</i> locus
JEH100	GCTCTGTTGAAGGCGGCCAA	External primer for <i>pdhS2</i> locus
JEH113	GCCGGTTTCATGCACACGCA	External primer for <i>pdhS2</i> locus
JEH146	GAAGAAGCTAGCGGCGAAAGACCGC CGG	cloning <i>pdhS2</i> w/o STOP and with NheI site
JEH147	GAAGAA <u>CATATGAGAG</u> AAAAAGCGG TCGCA	cloning <i>divJ</i> with NdeI site
JEH148	GAAGAAGCTAGCGGCGATTTTCGCT TTCGCGG	cloning <i>divJ</i> w/o STOP and with NheI site
JEH149	GAAGAAGGTACCTTATTTGTATAGTT CATCCATGCCA	cloning <i>gfpmut3</i> with KpnI site
JEH150	GAAGAAGCTAGCATGAGTAAAGGAG AAGAACTT	cloning <i>gfpmut3</i> with NheI site
JEH245	CGTGCGCAGCTCGgcCGACATGGAA GCG	<i>pdhS2</i> ^{CA811-812GC} mutagenesis
JEH246	CGCTTCCATGTTCGgcCGAGCTGCGCA CG	<i>pdhS2</i> ^{CA811-812GC} mutagenesis
JEH261	CGCACGAGCTGCGCgCGCCGCTCAA CGC	<i>pdhS2</i> ^{A823G} mutagenesis
JEH262	GCGTTGAGCGGCGcGCGCAGCTCGT GCG	<i>pdhS2</i> ^{A823G} mutagenesis
JEH282	<u>GGTACCTGCCAGAATCGTTGCT</u>	cloning <i>ccrM</i> promoter region, +222 bp to -9 bp from translational start, with KpnI site
JEH284	<u>AAGCTTTGCTGCCATTGGTACT</u>	cloning <i>ccrM</i> promoter region, +222 bp to -9 bp from translational start, with HindIII site
JEH285	<u>GGTACCTTAACCTTTCGTTTACGGGC</u> A	cloning <i>ctrA</i> promoter region, +328 bp to -9 bp from translational start, with KpnI site
JEH287	<u>CTGCAGAACCCGCATAATTATCCCCT</u> TT	cloning <i>ctrA</i> promoter region, +328 bp to -9 bp from

		translational start, with PstI site
JEH291	<u>GGTACC</u> ATTTGCAAGTGCCTCTT	cloning <i>pdhS1</i> promoter region, +264 bp to -9 bp from translational start, with KpnI site
JEH293	<u>AAGCTT</u> GGCGGGCATGTGCGAAA	cloning <i>pdhS1</i> promoter region, +264 bp to -9 bp from translational start, with HindIII site
USP073	GTTCCCTGAAACTTATTTTTCGTCTAT TTTTATCTTATA <u>AATTTT</u> GATAATCATC AGTAATTTTCATTTTGTAGGATTTCC	site-directed mutagenesis of CtrA binding site in <i>dgcB</i> promoter
USP074	GGAAATCCTACAAAATGAAAATTACT GATGATTATCAA <u>AATT</u> TATAAGATAAAA ATAGACGAAAAATAAGTTTCAGGGAA C	site-directed mutagenesis of CtrA binding site in <i>dgcB</i> promoter

REFERENCES

1. **Heindl JE, Crosby D, Brar S, Merenich D, Buechlein AM, Brugger EL, Waters CM, Fuqua C.** 2017. Reciprocal control of motility and biofilm formation by the PdhS2 two-component sensor kinase of *Agrobacterium tumefaciens*. bioRxiv.
2. **Kim J, Heindl JE, Fuqua C.** 2013. Coordination of division and development influences complex multicellular behavior in *Agrobacterium tumefaciens*. PLoS One **8**:e56682.
3. **Gao R, Stock AM.** 2017. Quantitative Kinetic Analyses of Shutting Off a Two-Component System. MBio **8**.
4. **Xu J, Kim J, Koestler BJ, Choi JH, Waters CM, Fuqua C.** 2013. Genetic analysis of *Agrobacterium tumefaciens* unipolar polysaccharide production reveals complex integrated control of the motile-to-sessile switch. Mol Microbiol **89**:929-948.
5. **Grangeon R, Zupan J, Jeon Y, Zambryski PC.** 2017. Loss of PopZ At activity in *Agrobacterium tumefaciens* by Deletion or Depletion Leads to Multiple Growth Poles, Minicells, and Growth Defects. MBio **8**.
6. **Simon R, Priefer U, Puhler A.** 1983. A broad host range mobilization system for *in vivo* genetic engineering: transposon mutagenesis in gram negative bacteria. Bio/Technology (Nature Publishing Company) **Nov.**:784-791.
7. **Gober JW, Shapiro L.** 1992. A developmentally regulated *Caulobacter* flagellar promoter is activated by 3' enhancer and IHF binding elements. Mol Biol Cell **3**:913-926.
8. **Akakura R, Winans SC.** 2002. Constitutive mutations of the OccR regulatory protein affect DNA bending in response to metabolites released from plant tumors. J Biol Chem **277**:5866-5874.
9. **Khan SR, Gaines J, Roop RM, 2nd, Farrand SK.** 2008. Broad-host-range expression vectors with tightly regulated promoters and their use to examine the influence of TraR and TraM expression on Ti plasmid quorum sensing. Appl Environ Microbiol **74**:5053-5062.
10. **Domian IJ, Reisenauer A, Shapiro L.** 1999. Feedback control of a master bacterial cell-cycle regulator. Proc Natl Acad Sci U S A **96**:6648-6653.
11. **Stephens CM, Zweiger G, Shapiro L.** 1995. Coordinate cell cycle control of a *Caulobacter* DNA methyltransferase and the flagellar genetic hierarchy. J Bacteriol **177**:1662-1669.
12. **Skerker JM, Shapiro L.** 2000. Identification and cell cycle control of a novel pilus system in *Caulobacter crescentus*. EMBO J **19**:3223-3234.
13. **Ramey BE, Matthyse AG, Fuqua C.** 2004. The FNR-type transcriptional regulator SinR controls maturation of *Agrobacterium tumefaciens* biofilms. Molecular Microbiology **52**:1495-1511.